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Abstract
Radiation therapy (RT) is a common treatment for brain neoplasms and is used alone or in
combination with other therapies. The use of RT has been found to be successful in
controlling tumors and extending the overall survival of patients; however, there are many
unanswered questions regarding radiotherapy effects in the normal brain surrounding or
infiltrated by tumor. Changes to the vascular and parenchyma have been documented, and
more recently inflammatory mechanisms have been postulated to play a role in radiation
injury. Traditional imaging techniques used within the clinic (CT and MRI) are often lacking
in their ability to differentiate between recurrent tumor, transient treatment effects, or
radiation necrosis. The primary goal of this thesis is to demonstrate an MRI acquisition
method that has been shown to be sensitive to deoxygenated blood and iron content as a
potential biomarker of radiation effect on the normal brain. Specifically, post-processing
techniques are used to determine the applicability of qualitative images such as
Susceptibility-Weighted Imaging (SWI) and quantitative methods such as Quantitative
Susceptibility Mapping (QSM) and apparent traverse relaxation (R2*) using the same
sequence. These methods are potential surrogate markers for vascular changes and
neuroinflammatory components that could predict sub-acute and long-term radiation effects.
Within this thesis, R2* is shown to be a promising marker for the prediction of radiation
necrosis, whereas SWI and QSM are shown to be excellent modalities for detecting longterm effects such as microbleeds. Additionally, R2* is shown to be a potentially useful
technique in identifying post-imaging treatment changes (pseudoprogression) following
chemoradiotherapy for malignant glioma. Finally, the use of this non-contrast method shows
promise for integration within a clinical setting and the potential for expansion to multicenter clinical trials.
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Scope of Thesis
The following is an overview of the chapters presented in this thesis.
Chapter One provides a review of the current clinical methodologies for diagnosing brain
tumors in patients as well as imaging techniques used in the follow-up of their therapy. The
current methods provide motivation for the use of the multi-echo gradient echo sequence that
is the overarching method utilized in this thesis.
Chapter Two contains a concise overview of the factors which influence magnetization and
thus signal in a gradient echo sequence. Through the use of magnetic field inhomogeneity,
the contrast from the magnitude and phase of the signal can be used to post-process images
which contain qualitative and quantitative information regarding the local magnetic
susceptibility of tissue.
Chapter Three presents an animal model of radiation necrosis measuring the apparent
transverse relaxation (R2*) over 28 weeks and retrospectively assessed to determine its use as
a predictive marker of radiation necrosis. The steady increase in R2* in the hippocampus and
internal and external capsule present a potential marker for the prediction of radiation
necrosis up to 10 weeks before morphological imaging.
Chapter Four provides a descriptive study on the long-term effects of radiation to the normal
tissue within the brain of patients treated for low-grade benign neoplasms. It demonstrates for
the first time that patients who receive radiation therapy alone could potentially be at an
increased risk of vascular disease due to the appearance of microbleeds within the high dose
region. Additionally, it demonstrates that white matter hyperintensities on FLAIR can be
detected with R2* and SWI while showing that these lesions are venocentric, a source of
significant research in other diseases such as multiple sclerosis.
Chapter Five describes a study in which R2* was used to differentiate patients who have nonspecific T1-gadolinium enhancement following chemoradiotherapy for malignant glioma. It
demonstrates that R2* can be used a marker to distinguish between patient progression and
treatment effect by the increased R2* in a patient’s T1 contrast enhancing lesion’s and
FLAIR’s non-enhancing lesion.
xv

Finally, Chapter 6 presents an overview of the findings in this thesis and seeks to expand on
the refinements for the experiments as well as discuss methods for implementation of this
technique for multi-center trials.

xvi
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Chapter 1

1

Brain Tumor Background

Glioma is one of the most common primary brain tumors in adults and may present as
low-grade (WHO Grade II), anaplastic (WHO Grade III) or Glioblastoma (WHO Grade
IV) with Grades III and IV often being grouped under the term “malignant glioma”.
Following treatment of glioma, the ability to determine treatment success is of utmost
importance to select the appropriate subsequent course of action. New advances in
medical imaging have given neuroradiologists the ability to characterize gliomas using
both anatomic and functional techniques. Combined with new therapies introduced in the
clinic, interpreting these multi-parametric medical images and determining the correct
course of management can become complex as imaging changes may reflect
combinations of treatment effect and tumor changes. When a malignant glioma patient
initially presents, the standard therapy consists of maximal surgical resection followed by
a course of Temozolomide (TMZ) chemotherapy and radiation therapy as suggested by a
clinical trial by Stupp et al. in 2009 1. More recent studies have suggested radiation and
chemotherapy may also be efficacious for patients with low-grade glioma 2,3. For
malignant glioma, combined chemotherapy has been shown to provide superior overall
survival (OS) of 14.6 months compared to 12.1 months for radiotherapy alone and has
proved to increase the progression-free survival (PFS) time to 6.9 months from 5 months.
At the time of malignant glioma recurrence, anti-angiogenic agents are commonly used
with PFS in the range of 6 months 4,5. Within the clinic, patient monitoring during and
shortly after therapy is necessary due to the high cost and toxicity associated with
continuing ineffective treatments and the potential detriment to patients by discontinuing
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effective treatments prematurely. For patients whose treatment was unsuccessful, their
inclusion in clinical trials of new therapies may be the best option if a true progression
diagnosis can be determined. The ability to differentiate true responders from nonresponders ensures patients fit the criteria for clinical trials and is important for
evaluating the efficacy of new agents studied on clinical trials 6.

1.1 Progression Free Survival as a surrogate marker for
Overall Survival
The success of therapies is traditionally gauged by the ability to improve the OS, which is
measured from the time of enrollment into a clinical trial until death from any cause.
Using OS as a marker of treatment success necessitates a longer follow-up period to
gauge OS and may provoke confounding effects caused by sequential therapies. As a
result, pre-clinical and clinical trials have begun to adopt alternate endpoints to help
determine the efficacy of treatments at earlier time points. For malignant glioma, PFS,
which is defined as the time from commencing therapy until evidence of disease
progression or death, is a potential replacement for OS. Within the glioblastoma
literature, Han et al. 7 demonstrated a strong correlation (R2 = 0.92) between OS and PFS.
As further pre-clinical research and clinical trials are conducted the use of PFS as a
marker of treatment success is becoming more prominent and allows the more efficient
evaluation of new therapies. A limitation of PFS is the ability to diagnose patients
correctly with true tumor progression as both clinical and imaging changes may reflect
the effects of therapies as well as the tumor.
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1.1.1

Confounding factors in assessing PFS

In most cases, patients will see symptoms improve due to the removal of the tumor and
response to radiation therapy and adjuvant chemotherapy. In addition to clinical
assessment, imaging is also performed to gauge response to treatment. During active
treatment, pseudoprogression and pseudoresponse are two treatment-related effects that
can confound the assessment of PFS and potentially lead to inappropriate patient
management by either over-calling (false positive) or under-calling (false negative) true
tumor progression.
Pseudoprogression is typically characterized by increased enhancement on a T1-weighted
gadolinium MRI following treatment with chemoradiotherapy; however, patients may be
clinically stable and may not exhibit symptoms that would typically be associated with
tumor progression. Currently, the most widely used standard of care is to continue
therapy for an additional 4-6 weeks and repeat imaging 8. In cases of pseudoprogression,
on early follow-up, imaging changes typically stabilize or improve. Whereas, within
cases of true progression, imaging changes will worsen. Correct interpretation of
pseudoprogression would prevent abandoning an effective therapy prematurely.
Pseudoresponse is a transient response to antiangiogenic drugs where the blood brain
barrier becomes re-established, leading to a decrease in vascular permeability and a
subsequent reduction in contrast enhancement on T1-weighted gadolinium MRI, rather
than true tumor response 9. Correct interpretation of pseudoresponse is important to avoid
continuing an ineffective therapy as tumors may progress in the absence of contrast
enhancement while on anti-angiogenic agents. To account for the possibility of
pseudoprogression and pseudoresponse, revised criteria that incorporate clinical and
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therapeutic information into the interpretation of images have been proposed 8. Even such
revised criteria are imperfect and objective imaging methods for the accurate
determination of tumor response or progression are needed. The following is an overview
of current imaging methods that propose to differentiate response from non-response as
well as pseudoprogression and pseudoresponse following treatment for glioma.

1.2 Conventional Imaging Techniques and Interpretation
1.2.1

CT Imaging

Computed tomography (CT) imaging was once regarded as the gold standard imaging
methodology and is still commonly used to rule out acute intracranial pathology such as
stroke. Prior to the introduction of MRI, CT was the primary imaging modality for the
evaluation of brain tumors. The Macdonald criteria 10 for assessing response based on CT
findings were developed and have been in widespread use ever since. Subsequently, the
Macdonald criteria has been adapted and revised from CT for its use in MRI 11 and later
evolved into the RANO and RECIST criteria described later in this article. Conventional
CT imaging is now seldom used in the clinic for the follow-up of patients who have been
treated for glioma, except for screening for acute pathology (such as acute bleed or
obstructive hydrocephalus) in the case of rapid clinical deterioration, or for surgical
guidance and radiation treatment planning. The use of CT perfusion as a potential
functional imaging technique for glioma is discussed in later sections.

1.2.2

Conventional MRI

Compared to CT, MRI offers superior soft-tissue contrast and has tremendously
improved the ability to diagnose brain tumors. The use of paramagnetic contrast agents
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for MRI in the 1980’s also allowed clinicians to understand the breakdown of the bloodbrain barrier and allow for improved diagnoses. Gadolinium agents play an essential role
in differentiating normal versus tumorous tissue and are used in conventional MRI
imaging following treatment; however, some non-contrast methods that aid in
differentiation are slowly being introduced into everyday clinical use and include
sequences such as Diffusion-Weighted MRI and Magnetic Resonance Spectroscopy
(MRS).

1.2.2.1

Typical Scan Parameters

Following completion of treatment, all patients have a follow-up MRI to determine
whether the treatment was effective. Currently, 1.5 T MRIs and 3 T MRIs are commonly
used in clinical settings. A consensus group assembled in 2015 recommended that at a
minimum, the sequences listed in Table 1.1 be acquired as part of a standard imaging
protocol for glioma 12. The consensus group also suggested acquisition parameters for
various MRI manufacturers.
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Table 1.1 Recommend Acquisitions for patients undergoing MRI for glioma. Postcontrast T1-weighted image were used for the MacDonald and RECIST criteria,
while RANO incorporates the post-contrast T1-weighted image as well as FLAIR.
1.

Pre-Contrast T1weighted mage

2.

Axial 2D or 3D
FLAIR

IR-GRE Sagittal or axial
acquisition
Scan time 5-10 minutes
TSE or FSE
Scan time 4-8 minutes

3.

Axial 2D T2weighted image

TSE or FSE
Scan time 2-4 minutes

4.

Axial 2D Diffusion
Weighted Image

Single-shot EPI
2-4 minutes for 3 b-values and 3
directions

5.

Post Contrast T1weighted image

IR-GRE Sagittal or axial
acquisition
FA 10-15º
Same parameters as pre-contrast
image

The images obtained in Table 1.1 form a basis to assess the treatment response of tumors.
Until 2010, the MacDonald criteria was used extensively for 2D measurements of the
gadolinium-enhancing lesion area and the RECIST criteria was used as a substitute with
only 1D measurements along the long axis. With newer therapeutics and imaging
capabilities (e.g. non-contrast imaging such as FLAIR) a re-evaluation of the methods
was necessary and evolved into the RANO criteria that uses 2D measurements of the
gadolinium-enhancing lesion as well as FLAIR lesion 13. In 2010, the RANO working
group suggested alternate guidelines to assist in differentiating between responders and
non-responders. The guidelines could also distinguish pseudoprogression and
pseudoresponse by incorporating information from multi-parametric MRI as well as
clinical and therapeutic information8. In 2015, further guidelines from the RANO
working group were released for patients receiving immunotherapy 14 to address the
delayed response to therapy and therapy-induced inflammation.
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The current RANO criteria measures the largest five lesions in a 2D plane along their
longest diameters in two perpendicular axes as shown in Figure 1.1. The sum of these
areas produces the sum of the product of diameters (SPD). This measurement should be
done after surgery but before treatment to form a baseline measurement. Following the
baseline scan, measurements should be done after each subsequent MRI. These
measurements compared to the baseline SPD constitute the basis to determine whether
there is a complete response, partial response, stable disease, or progressive disease as
shown in Table 1.2.

Figure 1.1 Demonstration of how to calculate the SPD in RANO criteria. Two
lesions are shown, but 5 lesions must be calculated.
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Table 1.2 Summary of possible diagnosis and guidelines for use of the RANO
criteria.
Status
Complete
Response
Partial Response
Stable Disease
Progressive
Disease

Definition for T1-Gd
enhancement
All target lesions
disappeared
(potential for
pseudoresponse)
SPD decreased by at
least 50% of baseline
value
SPD between a 50%
decrease and 25%
increase
SPD increased by at
least 25% (potential of
pseudoprogression)

T2-weighted FLAIR
Area
Stable or
decreasing

Clinical Status
Stable or improving

Stable or
decreasing

Stable or improving

Stable or
decreasing

Stable or improving

Increasing

Decreasing

The RANO criteria also accounts for pseudoresponse and pseudoprogression with these
measurements. In pseudoresponse, a patient’s gadolinium-enhancing MRI typically will
have a significant decrease within days of starting of anti-angiogenic therapy; however,
since the tumor cells may co-opt blood vessels in the brain, the tumor may develop into a
non-enhancing phenotype 15. The co-opting of blood vessels is a mechanism in which
tumor cells obtain a blood supply from the pre-existing vasculature leading to potential
metastasis 16. The RANO criteria accounts for this by taking a measurement of the
FLAIR’s lesion area. If the FLAIR hyperintensities remain stable or increase, the lesion
is marked as progressive disease.
As previously noted, pseudoprogression is a condition that initially appears to be a
progressive disease following treatment due to new lesions or growth of lesions within
the radiation treatment areas. According to the RANO criteria, no determination of
pseudoprogression or true progression should be done until 12 weeks following therapy
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unless the new enhancing areas are outside the radiation treatment volume, the patient
exhibits clinical deterioration, or other methods can definitively rule out
pseudoprogression (e.g. repeat resection demonstrating viable tumor).

1.2.2.2

RANO Drawbacks

While RANO represents a significant consensus effort to standardize imaging
interpretation in the era of new therapies, it remains an imperfect tool. Kazda et al.
demonstrated that the RANO criteria does not correlate well with a clinician’s assessment
of progression in anaplastic astrocytoma based on a composite of neurological symptoms
and imaging 17. The authors also suggested this may be specific for anaplastic glioma or
other WHO Grade 3 tumors as they typically have poor contrast enhancement. The
authors emphasize the importance of considering the entire clinical context such as
change in neurologic function or symptoms in addition to imaging measures of response
(including quantitative methods such as RANO or RECIST).
Perez-Larraya et al. set out to study the usefulness of the RANO criteria compared to the
MacDonald criteria, RECIST, and RECIST + FLAIR in patients treated with
Bevacizumab 18. Their results showed that correlation of the median PFS following
treatments with imaging was not statistically significant with any of the criteria. Their
results further validated the usefulness of FLAIR, as defined by the RANO and RECIST
+ FLAIR criteria, to avoid the overestimation of PFS in patients and commented that with
the integration of FLAIR in both 1D and 2D methods, RECIST has similar response rates
compared to the RANO criteria. Thus, while the RANO criteria represents an
improvement in response assessment that reflects newer therapies and imaging
modalities, there are clinical situations where existing imaging may be ambiguous (e.g. at

10

early time points following chemoradiotherapy or response to antiangiogenic agents). In
these situations, newer imaging analyses or modalities may be beneficial and will be
discussed in the following sections.

1.3

Diffusion Weighted Imaging

A Diffusion Weighted Image (DWI) is a common sequence acquired as part of a
multiparametric MRI imaging study for CNS tumors. The most common metric
calculated from DWI is the Apparent Diffusion Coefficient (ADC). ADC provides
information regarding water molecules’ ability to freely diffuse. In areas of high
cellularity, such as tumor, the water cannot diffuse as easily and has a restricted diffusion
or low ADC values (visualized as darker areas on reconstructed ADC images). In areas of
necrosis or within cysts, increased ADC values reflect less impeded water diffusion
(represented by brighter areas on ADC images).
In order to calculate the ADC, diffusion gradients of at least b=1000 s/mm2 and b=0
s/mm2 (no diffusion weighting) are recommended, although having an extra diffusion
gradient at b=500 s/mm2 will increase the quality of the computation 12. For ADC
measurements, the b-value is an indicator of the strength of the diffusion gradient applied
along at least three axis. The applied b-value of the gradient is inversely related with the
diffusion distance of water molecules, meaning a high b-value will be preferential to
water molecules with restricted diffusion. The Stejskal-Tanner model for the pulsed
diffusion method is defined with the following equation 19:
δ
𝑏 = 𝛾 & G& δ& (Δ − )
3

1.1
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where 𝛾 is the gyromagnetic ratio (Hz/T), G (T/m) is the strength of the gradient,
δ (seconds) is the duration of the gradient pulse, and Δ is the time between diffusion
gradients Most clinical scanners have the software to compute ADC online. Bulik
suggested that a mean absolute ADC value of 1.3 x10-3 mm2/s or lower within the tumor
volume could be a cutoff for glioblastoma relapse compared to pseudoprogression 20
based on a series of 24 patients (sensitivity and specificity of 100% and a P < 0.001).
Applying such a threshold should not be done without other a priori knowledge, as noted
by the authors who observed that acquisition methods and other factors such as tissue
necrosis and vascularity may confound the computation of ADC.
In response to these confounding factors, further studies have investigated metrics other
than mean ADC, such as fifth percentile ADC, maximum ADC, and minimum ADC.
Additionally, other metrics can be computed when acquiring Diffusion Tensor Imaging
such as Fractional Anisotropy; however, to date, such methods have not demonstrated
high sensitivity and specificity without the inclusion of other imaging modalities and
intervention from the neuroradiologist. 21
Chu et al. have shown that higher b-value (b=3000 s/mm2) gradients can be used to
differentiate pseudoprogression and true progression using the ADC’s histogram at the
expense of relative signal intensity at the high b-value. They found that by using the fifth
percentile of ADC values within an enhancing lesion, true progression can be
differentiated from pseudoprogression using different b-values. (b=1000 mm2/sec
P = 0.049, b=3000 mm2/sec P < 0.001) 22.
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The obvious limitation of such methods is that the fifth percentile of all voxels within the
tumor disregards 95% of the information and may not take into account the heterogeneity
of the lesion.
Baseline mean ADC using the lower Gaussian curve of a double Gaussian distribution
has also been shown to be a statistically significant marker of PFS and OS following
treatment with Bevacizumab. Using a mean pretreatment threshold value of 1.2 x 103

mm2/s, patients with a high ADC pretreatment had a significantly longer PFS (153 days

versus 76.5 days, P = 0.045) and OS (376 days versus 194 days, P = 0.003) 23.
A comprehensive review of published ADC data concluded there is a potential for using
the baseline minimum ADC value due to its inverse correlation with tumor grade and
PFS 24. Using previously obtained data over a 1.5 year observation period, with ADC
cutoffs ranging from 0.6 x10-3 mm2/s to 1.0 x10-3 mm2/s, a statistically significant
difference in mean survival rate was observed (73.8% above cutoff, 22.7% below cutoff,
P<0.001).
Texture analysis can also be used for second order analysis of the ADC values within the
tumor. Measures such as entropy, skewness, and kurtosis can be calculated based on the
heterogeneity of the ADC values. Ryu et al. 25 demonstrated that the grading of glioma is
feasible using these metrics to differentiate Grade 2 and 3 tumors from Grade 4 tumors.
Entropy as a measure of grading glioma yielded a higher sensitivity and similar
specificity (78.1% and 87.5%) compared to the fifth percentile ADC values (59.4% and
87.5%).
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Brynoflsson et al. performed a more complex method using principal component analysis
to determine a pseudoscore. Their methods demonstrated that many of the second order
factors, as well as certain first order features, could identify two groups in their data with
a median survival of 1099 days in one group and 345 days in another group (P = 0.001).
26

As a whole, the usefulness of ADC as a pretreatment prognostic factor and as an
assessment of response remains ambiguous. A further limitation is the potential
variability between vendor and imaging protocol. Tsujita et al. demonstrated significant
variability between scanner types and ADC values in healthy brain 27; however, the
variability between vendor types was on the same scale as between patients. In brain
tumors, it is possible that the heterogeneity of ADC values within tumors or necrotic
tissues may often confound routine quantitative methods; however, the quick acquisition
time relative to the entire study time makes its acquisition worthwhile, and
standardization of ADC acquisition and development of generalizable metrics remain
goals of ongoing research.

1.4
1.4.1

Perfusion
Perfusion CT

While contrast-enhanced CT provides inferior anatomic imaging compared to MRI, the
quantitative nature of CT allows for more accurate determination of functional
parameters such as blood flow. Perfusion CT is a very quick method to determine blood
flow within the brain using a nonionic contrast and relies on the rapid acquisition of serial
CT images throughout a constant brain volume during the injection of a bolus of contrast
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material. Tracking passage of contrast through a brain region over a fixed time period
allows for the calculation of a variety of vascular parameters. For example, relative
Cerebral Blood Volume (rCBV) is a measure of blood volume in a selected area of tissue
relative to normal brain (typically white matter) and is calculated by measuring the area
under the concentration-time curve. Relative Cerebral Blood Flow (rCBF) is a measure of
blood volume that passes within an area of tissue in a specific amount of time and is
calculated by deconvolving the concentration-time curve with the arterial input function
to get the tissue response function. The height of the tissue response function is the
measured CBF, while the rCBF is the ratio of CBF to normal brain. Another parameter
that is acquired is rMTT, a measure of average time blood spends within the capillary
circulation and is calculated by dividing the area under the concentration time curve by
the height of the tissue response function (rCBF). Depending on the processing either
rMTT or rCBF is calculated and their relation is as follows: CBV =CBF*MTT.
A rCBV threshold of 1.92 has been shown to differentiate between low and high-grade
tumors with a sensitivity of 85.7% and specificity of 100%
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in 19 patients. The same

group also demonstrated that perfusion CT had significant differences between patients
with treatment necrosis compared to recurrent tumor using rCBV, rCBF, and rMTT.
Specifically, a lower rCBV (1.2±0.3 versus 2.1±0.7; P<0.001), lower rCBF (1.2±0.5
versus 2.6±1.7; P = 0.004), and higher rMTT (1.4±0.4 versus 1.0±0.4; P = 0.018) was
predictive of treatment effect
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. The use of perfusion CT is a quick and economical

alternative to perfusion MRI (discussed in section 1.4.2) and is readily available in many
imaging departments as perfusion CT has become a standard of care for stroke imaging.
While concerns about cumulative radiation dose delivered by CT perfusion (as may be
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necessary to monitor glioma) are being addressed through low dose CT techniques, the
resolution of soft tissue with CT remains inferior to MRI, which may limit its adoption as
a standard imaging technique in assessing tumor response.

1.4.2

Perfusion MRI

Like perfusion CT, perfusion MRI seeks to characterize vascular parameters in the tumor.
There are two primary techniques used for perfusion MRI. Dynamic Contrast
Enhancement (DCE, also referred to as permeability MRI), is a T1-weighted sequence
and like perfusion CT, uses images that are acquired before, during, and after injection of
a contrast agent. The serial acquisition of the T1-weighted images allow for a
measurement of the signal intensity over time that reflects the tissue’s perfusion, vessel
permeability, and extravascular-extracellular space 30. This method offers an advantage
over the traditional static T1-weighted gadolinium image. The tissue’s response to
contrast can be observed and quantified with derived parameters such as kTrans, a
reproducible measure of permeability in glioma patients, or Area Under the Curve Ratios
(AUCR) 31,32 a measure of the ratio between area under the curve at wash-in and washout. For example, Suh et al. demonstrated that when using T1-weighed DCE, the ratio
between the wash-in and wash-out AUCR is statistically significant different (P < 0.001)
between pseudoprogression and true tumor progression groups 33. The sensitivity and
specify of this method varied based on the method in which the cumulative AUCR was
calculated (i.e. 25th percentile, 75th percentile, etc.) but were between 73-90 %.
Dynamic Susceptibility Contrast (DSC) imaging is a T2 or T2* weighted sequence also
known as bolus tracking MRI and relies on serial imaging to track contrast flow through
the brain. In DSC, the magnetic susceptibility of the contrast leads to a decrease in signal
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intensity that can be measured and converted into parametric maps of CBV and CBF 34.
Derived parameters from DSC in MRI include the rCBV (similar measurement to
perfusion CT), rPH (ratio between the peak height within an enhancing lesion versus
normal white matter) and PSR (percent signal recovery of the signal intensity after a first
pass of contrast bolus). Within neuro-oncology, the vascular leakiness of tumors and
pooling of blood make rCBV the most widely used parameter as the contrast causes
changes in both T2 and T2* sequences, providing robust measurement 35. A study by
Young et al. demonstrated that the rCBV and rPH were significantly higher in groups
with true progression compared to pseudoprogression while the percent signal recovery
(PSR) was significantly greater in the pseudoprogression group 36. They determined that
a rCBV <1.8 yielded a sensitivity and specificity of 100% and 75% respectively, while a
rCBV < 2.4 yielded a 69% sensitivity and a 100% specificity for differentiating
progression from pseudoprogression. They also demonstrated that a cutoff rPH of 1.7
achieved 100% sensitivity and specificity in differentiating true progression from
pseudoprogression. Gahramanov et al. demonstrated a similar rCBV value cutoff with a
different contrast agent (Ferumoxytol) 37. The use of the rCBV cutoff with Ferumoxytol
was also associated with a statistically significant hazard ratio (median OS for high rCBV
163 days, median OS for low rCBV 591 days, hazard ratio 0.098, P = 0.004). In the same
study, correcting the standard perfusion contrast (Gadoteridol) for leakage produced a
statistically significant hazard ratio (0.12, P = 0.003).
Standardization of CBV is a process in which the CBV is transformed into a unitless
consistent intensity scale that is independent of scanner vendor 38. The use of
measurement of standardized rCBV pre and post-Bevacizumab has been shown to have
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statistically significant results for OS, and post-Bevacizumab has proved to be indicative
of PFS 39. In this study, if the unitless standardized rCBV ranged from 0 to 50000, where
0 indicated no rCBV and 50000 was rCBV typically found in large vessels. For
pretreatment standardized rCBV below 4400, the mean OS was shown to be 380 days
compared to 175 days (P = 0.024). A standardized rCBV below 4400 after Bevacizumab
was shown to have a PFS of 167 days compared to 78 days (P = 0.006).

1.5

Susceptibility-Weighted MRI

One of techniques used in this thesis is Susceptibility-Weighted MRI (SWI), explained in
further detail in the next chapter. Due to the vascular nature of tumors, SWI is slowly
being recognized as an alternative to standard imaging techniques as it is sensitive to
vascular changes.
SWI can be done with or without the use of gadolinium contrast. A study by Sayyari et
al. indicated that SWI could be better suited for delineating the tumor when using
contrast, especially when identifying the lesion on SWI (CE-SWI) for measurement in
ADC 40. They showed that the CE-SWI lesion was significantly smaller than the
gadolinium-enhancing T1 lesion (P = 0.002 first time point, P = 0.004 second time point).
Additionally, this study used parametric tests on a patient-by-patient basis showing
elevated ADC for patients with pseudoprogression or stable disease and decreased ADC
in tumor progression. Additionally, they found that using CE-SWI as a contrast mask for
ADC measurements allowed for proper classification as opposed to the gadolinium
enhanced T1 lesion. Fahrendorf et al. have recently demonstrated an increased ability to
delineate the tumor invasion zone of a high-grade glioma using contrast-induced phase
shift (CIPS) between a contrast enhanced and non-contrast SWI 41 allowing better
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delineation of tumor extension beyond the boundaries detected by T1 gadoliniumenhanced MRI. They further elaborate that CE-SWI could be a better imaging technique
for visualization of the tumor invasion zone compared to gadolinium-enhancing T1 and
FLAIR, especially in smaller tumors, but recommended further study among a variety of
glioma phenotypes.
Promising work with non-contrast SWI may lie with the processing of quantitative data
using a multi-echo gradient echo sequence. The multi-echo sequence allows for
measurement of the apparent transverse tissue relaxation (R2*) and further processing of
phase can be performed to compute measures of Quantitative Susceptibility Mapping
(QSM). A feasibility paper demonstrated the ability to differentiate blood deposits and
calcification using QSM 42, suggesting that QSM would be useful to identify
oligodendroglia variants of high-grade glioma (calcification being more common in
oligodendroglial tumors) and to monitor for calcifications developing in tumors.
SWI has also been used to identify microbleeds following the treatment of glioma as well
as monitoring patients following anti-angiogenic therapy 43. Lupo et al. showed that
patients receiving chemoradiotherapy for malignant glioma had increased micro-bleed
formation two years post radiation while patients receiving anti-angiogenic therapy had
fewer microbleeds overall following treatment. These authors, among others, postulate
that anti-angiogenic drugs could have a radioprotective effect on the microvasculature.
The main drawback of SWI and its associated quantitative methods is the lack of
standardization for post-processing leading to subjective interpretation of the data 44.
Additionally, gradient-echo sequences are more susceptible to motion, poor magnetic
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field shims, and titanium clips that may be used in brain surgery. Furthermore, there is
limited clinical information that correlates SWI imaging techniques with clinical
outcomes in the treatment of glioma. Thus, its performance in differentiating true
progression from pseudoresponse and pseudoprogression remains to be determined.

1.6

Other Imaging Modalities

There exist many other experimental techniques in the diagnosing and follow-up of brain
tumors. MRI techniques such as spectroscopy have been used in the clinic and can help
identify patterns of important brain metabolites like NAA, Choline, and lactate. Other
techniques such as Chemical Exchange Saturation Transfer (CEST) and hyperpolarized
C-13 may provide imaging information at a molecular level regarding tissue pH and
metabolism. Nuclear medicine tracers for Single Photon Emission Computed Topography
(SPECT) and Positron Emission Topography (PET) are also areas of active research in
attempting to understand the metabolism and molecular profiles of tumors, treatment
effect, and radiation necrosis. While it is necessary to be aware of such methods and their
results when developing experiments, for this work they are not elaborated upon. These
methods are either referenced or discussed, when relevant, in subsequent chapters.
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Chapter 2

2

Quantitative and Qualitative Imaging with Multi-Echo
Gradient Echo Imaging

The previous chapter reviewed the current methodologies for glioma imaging. It
demonstrated how edema (measured through FLAIR or ADC) and the relationship of
blood volume and flow (measured through perfusion) have been instrumental in the
advancement of the diagnosis and monitoring of brain neoplasms. This chapter seeks to
describe the motivation behind the use of qualitative images and quantitative
measurements obtained from multi-echo gradient echo (ME-GRE) sequence.
In general, gradient echo imaging has become more commonplace 1 due to better
magnetic field homogeneity and is used in many applications. Gradient-echo sequences
differ from spin-echoes sequences by having a lower flip angle and lack of a refocusing
pulse. This has a distinct advantage at increasing magnetic field strengths as limitations
on transmit radiofrequency (RF) field homogeneity, and Specific Absorption Ratio
(SAR) can be problematic 2.

2.1

Signal and Bulk Magnetization

By placing a sample within a magnetic field it will exhibit a bulk magnetization (Mz)
parallel to the magnetic field (B0) as shown in Figure 2.1. The bulk magnetization will
precess at a certain frequency related B0 and the gyromagnetic ratio, 𝛾 = 42.577 𝑀𝐻𝑧/
𝑇, as shown in equation 2.1:
𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 = 𝛾 ∗ 𝐵J [2.1]
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Applying a radio-frequency pulse to the sample will “tip” the bulk magnetization into the
transverse plane.

Figure 2.1 Example of bulk magnetization aligned along B0 (left) and tipped into the
x-y plane (right).
Figure 2.1 illustrates the x’-y’ axis as the transverse plane relative to the rotating
reference frame that precesses at the frequency in equation 2.1.
When tipped into the transverse plane, the bulk magnetization is placed into a nonequilibrium state, and the magnetization will return to equilibrium through spin-lattice
(T1) and spin-spin (T2) relaxation. The precessing magnetization in the transverse plane
induces a signal in a RF coil.
The net magnetization has a linear relationship with the external magnetic field.
Therefore, higher field strengths allow for the potential of higher resolution imaging,
faster acquisitions, or a combination of both.
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2.1.1

Spin-Lattice Relaxation

One process by which the magnetization returns to equilibrium is through R1 (R1=1/ T1)
relaxation. In its simplest form, this relaxation is a process in which the magnetization
returns to equilibrium in the z-direction through interactions with the surrounding
environment (lattice). T1 increases with field strength and is not a contributing source of
signal loss or contrast when using gradient-echo imaging for T2* weighting as a small flip
angle is used (i.e. <15º) and pulse sequence repetition time (TR) is much faster than T1
relaxation. T1 is defined as the amount of time for the bulk magnetization to reach 63%
(1-e-1) of its original magnetization along z.

2.1.2

Spin-Spin Relaxation

Another process by which the magnetization returns to equilibrium is through R2
relaxation (R2 = 1/ T2). R2 relaxation is due to tissue-specific spin-spin interactions which
cause spins within a voxel to lose their coherence. The loss of coherence results in decay
of the net magnetization in the x-y plane over time. In addition to these spin-spin
interactions, spatial magnetic field variations may compound the loss of coherence
causing the observed relaxation to be faster than the tissue specific relaxation. These
spatial magnetic field variations are characterized by the additional terms R2’ (relaxivity
caused by magnetic field inhomogeneities) and R2* (relaxivity from all sources) with their
relations expressed in the following equations:
1
1
1
+ N
∗ =
𝑇&
𝑇& 𝑇&

2.2 𝑎
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𝑅&∗ = 𝑅& + 𝑅&N [2.2 𝑏]
In spin-echo imaging component of the loss of coherence can be recovered through the
use of a 180° refocusing pulse; however, in gradient echo imaging the refocusing pulse is
not used, resulting in a faster decay of the spin coherence. The contributing effects of
magnetic field inhomogeneity, which causes the dephasing, can be largely attributed to
the mesoscopic field and the macroscopic field that will be defined in the following
section.
It should be noted that the effects of the macroscopic and mesoscopic field can be a factor
in spin-echo imaging. As molecules diffuse over time, they may be exposed to variations
in the magnetic field. Being exposed to variation of the magnetic field will result in
molecules not being “refocused” when using the refocusing pulse. The choice of time
between the excitation pulse and refocusing pulse (or multiple refocusing pulses) is an
important consideration when using spin-echo sequences to measure contributions that
arise only from the T2 decay.
The T2 (or T2*) time constant is defined as the amount of time needed for 37% of the
signal to decay in the transverse plane (e-1).

2.2

Influence on signal

As previously mentioned, in T2*-weighted MRI there are two main contributing factors to
the signal decay in the transverse plane in addition to T2 decay. They are, 1) the variation
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of the macroscopic field that is slowly varying across the sample and 2) the mesoscopic
field that influences the local magnetic field on a submillimeter scale.

2.2.1

Macroscopic Field

The variation of the macroscopic magnetic field is typically on the order of many
imaging voxels. Variations of the macroscopic field are caused by air-tissue susceptibility
differences 3–5 or general magnetic field imperfections that arise from placing an
inhomogeneous sample within the scanner. Before imaging, major variations of the
magnetic field can be “shimmed” by using various orders of shimming coils to offset the
magnetic field variations.

2.2.2

Mesoscopic field

The mesoscopic field provides useful local information regarding the magnetic field
inhomogeneity that is caused by paramagnetic or diamagnetic substances. In addition to
affecting the local T2* that causes changes in the magnitude image, its influence can be
detected on filtered phase images (discussed further in section 2.3).

2.2.2.1

Paramagnetism

Paramagnetism is caused by certain materials with unpaired electrons enhancing the main
magnetic field. In humans and animals, MRI paramagnetism is often attributed to the
presence of iron. Sources of iron include deoxygenated blood, originally shown by
Ogawa 6, hemosiderin, or increases in iron content due to inflammation 7,8.
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2.2.2.2

Diamagnetism

Diamagnetism is caused by materials that are repelled by the main magnetic field and
induce an opposite local magnetic field. Typically, myelin, cerebral spinal fluid, and
calcifications are diamagnetic 9.

2.2.2.3

Paramagnetism and Diamagnetism as a Source of
Contrast

Both paramagnetic and diamagnetic compounds affect the local magnetic field in such a
way as to influence T2*; however, when it comes to measuring the accrued phase, which
is discussed in the next section, one must set a reference value. While the measured phase
is referenced to the global frequency over the sample, the interpretation of such data
would make quantification between patients and between sites difficult. To overcome this
limitation, common areas such as the frontal or occipital white matter are used as a
reference 10,11. Using the white matter as a reference, paramagnetism will produce a
decrease in accrued phase while calcification and CSF will result in an increase in phase
accrual.

2.3

Multi-echo gradient echo imaging

Signal acquired from MRI imaging is inherently complex valued and can be recombined
as a complex valued image. In most clinical applications the phase is discarded, and only
the magnitude image is viewed; however, within the research setting the phase provides
complementary information that can be used to enhance images (discussed in 2.3.2).
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Post-processing techniques include forming magnitude images as well as phase (or
frequency) images.

2.3.1

Magnitude

Figure 2.2 shows the magnitude image of three separate echoes from a six-echo gradient
echo acquisition. The magnitude of the image is simply the absolute value of the complex
data acquired from the scanner. It can be observed that there is an increase in T2* related
contrast with longer echo times. Echo 1 has a more proton density-like contrast while
Echo 6 has pronounced T2* weighting contrast due to the strong differential decay of
regions with different T2* values. An advantage of multi-echo imaging is that an average
of all magnitude images can be created to simplify visualization and potentially increase
signal-to-noise ratio.

Figure 2.2 Example of various echoes acquired from a multi-echo gradient echo
sequence and an average image of all echoes. TR: 40 ms, FA 13°, TE1=3.75 ms,
TE3=11.95 ms, TE6=24.25 ms.
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2.3.2

Phase

As previously discussed, the MR signal received from the magnetization is a complex
vector. The orientation of the magnetization vector within the transverse plane can be
described by a phase(𝜑). The measured phase arises from differences in the z component
of magnetic fields (microscopic, mesoscopic, and macroscopic) over a sample causing
slight variations in frequency in the range of 1-100 Hz. While the main nuclear
precession frequency is linearly related to the main magnetic field and the gyromagnetic
frequency as was shown in equation 2.1, differences in the main magnetic field can be
expressed much the same way, as shown in equation 2.3 and 2.4.
∆𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 = 𝛾∆𝐵

2.3

Where ∆𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 is the change in frequency and ∆𝐵 is the change in magnetic field.
The frequency offset measured at a specific echo time (TE) can be characterized as the
accrued phase (𝜑).
𝜑 = 𝛾∆𝐵 ∗ 𝑇𝐸 [2.4]
In equation 2.4 the ∆𝐵 term are contributions from both the local and global field
inhomogeneity; however, the phase contrast that is due to the local variations of magnetic
field inhomogeneity (i.e. mesoscopic and microscopic field) is of most interest. In order
to extract such detail, the acquired phase must be further processed.
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2.3.3

Unwrapping and Filtering

The phase of the complex image acquired from the MRI is inherently bound between [-𝜋
to 𝜋] due to the nature of signal acquisition. This wrapped phase is not an accurate
representation of the true relative phase within an image as the accrual of phase can be
greater than 2𝜋. The relationship between wrapped phase and unwrapped phase is shown
in equation 2.5:
𝜑(𝑟)VWXYZ[[\] = 𝜑(𝑟)XYZ[[\] + 2𝜋𝑚 [2.5]
Where m is a positive or negative integer accounting for the number of wraps. An
example of wrapped phase is shown in the top row of Figure 2.3.
Phase unwrapping attempts to remove any integer (m) of 2 𝜋 from the image, and
methods to unwrap phase that are acquired with a single echo are not trivial12,13. With
multiple echo imaging, it is possible to set the relative phase of the first image to zero
during reconstruction, and temporally unwrap the remaining echoes 14. As such, only five
echoes from a six echo sequence have information regarding the phase. Any remaining
spatial wraps can be removed by adding or subtracting 2𝜋 at an area of wrapped phase.
This unwrapped phase contains contribution of the local mesoscopic field and global
field. The corresponding unwrapped phase is also shown in the middle row of Figure 2.3.
Once the unwrapped image is computed, the final stage is to remove the contributions of
the globally varying magnetic field. As previously mentioned, these components have
low spatial frequency and can be filtered using a Gaussian high-pass filter. An example
of the filtered image is shown in bottom row of Figure 2.3.
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Figure 2.3 Examples of Wrapped Phase, Unwrapped Phase and Filtered Phase using
a Gaussian high-pass filter for the second and sixth echo after processing the first
echo to have zero phase.
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While high-pass filtering is shown in Figure 2.3, other methods can remove the unwanted
background field such as homodyne filtering 8,15, SHARP filtering 11, or Projection onto
Dipole Fields 16. All these techniques offer the ability to remove the unwanted
contribution from the global field while retaining the local information. The amount of
filtering that is performed is largely user and center specific, with a lack of
standardization across sites. This lack of standardization causes the definition of global
field variations and local field variations to differ between sites.

2.3.4

Post-Processing Techniques

Using the above data set, images can be processed into a final form that is viewable and
provides qualitative or quantitative information. Methods such as SusceptibilityWeighted Imaging (SWI), Quantitative Susceptibility Mapping (QSM), or apparent
transverse relaxation (R2*) are typical images that are computed with multi-echo gradient
echo.

2.3.4.1

SWI

Susceptibility-Weighted Imaging, originally called BOLD venographic MRI 17, is a
method in which the phase data can be used to enhance a magnitude image. The multiecho technique is focused on computing a frequency mask, which is calculated by doing
a least squares weighted fit through the multiple echoes 18. Rewriting equation 2.4 and
only taking into account the variations in local magnetic field the relationship between
frequency and phase can be expressed as follows:
𝜑
= 𝛾∆𝐵_`aZ_
𝑇𝐸

2.6 𝑎
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∆𝐹_`aZ_ =

𝛾
∆𝐵
2𝜋 _`aZ_

2.6 𝑏

where the ∆𝐹_`aZ_ can be expressed in hertz or radians (dependent on the 2𝜋 term). This
step is used in multi-echo SWI to provide a single image that is representative of the
Local Frequency Shift (LFS). The LFS represents the changes in frequency within a
voxel that is caused by the mesoscopic and microscopic field. The LFS map is used as a
substitute for a phase-mask that can also be calculated based on the relationship in
equations 2.6a and 2.6b. From this step, an appropriate frequency mask as shown in
equation 2.7 can be created to process the LFS in a way that is sensitive to paramagnetic
compounds such as deoxygenated blood, hemosiderin, or iron.
1 𝑖𝑓 ∆𝐹_`aZ_ > 0

𝑚𝑎𝑠𝑘 =

∆𝐹_`aZ_
+ 1 𝑖𝑓 𝑓aVj < ∆𝐹_`aZ_ < 0
|𝑓aVj |
0 𝑖𝑓 ∆𝐹_`aZ_ < 𝑓aVj

[2.7]

The above mask causes any positive frequency to be set to 1, preserving the contrast in
the magnitude image. Any negative frequency larger than a specified cut off is set to 0,
with a linear transition between the cutoff frequency and 0. This amplifies the effect of
negative frequency shifts on the magnitude image, yielding superior contrast, especially
in the visualization of paramagnetic compounds such as deoxygenated blood. The linear
transition is arbitrary and can be replaced with any transition function, or the mask could
simply be a step function at 𝑓aVj = 0. Allowing for a gradual transition can provide for a
smoother transition of negative frequency between 0 and 𝑓aVj providing for more pleasing
contrast in the images 18.
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The final step is to multiply the mask into the magnitude. The image can be multiplied n
times, to enhance the visualization of the negative frequency components; however, too
many multiplications may increase the noise of the image. A multiplication of 3-5 times
often yields high contrast while limiting noise 4,18. An example of the implementation of
SWI is shown in Figure 2.4.

Figure 2.4 Example of the post-processing technique used to calculated SWI
One can take the additional step of using a minimum intensity projection through many
slices to visualize veins that may appear in adjoining slices. This is often useful when
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trying to distinguish veins from pathologies such as microbleeds, a topic which will be
discussed in the subsequent chapters.

2.3.4.2

Quantitative Susceptibility Mapping

As was shown in equation 2.4 the accrued local phase is related to the product of the
gyromagnetic ratio, changes in local magnetic field (∆𝐵), and TE. While this is useful for
calculating the change in frequency as shown in equation 2.6, it is also possible to extract
information about the susceptibility of the tissue within a voxel r. The magnetic field
variation is related to the magnetization and the point-dipole response 19 as shown by the
convolution in equation 2.8

∆𝐵(𝒓) = 𝜇J 𝑀(𝒓)

𝐺 𝒓

[2.8]

where M(r) is the local magnetization along B0 (or z-direction), and G(r) is the Green’s
function for the point-dipole response function.
1 3 𝑐𝑜𝑠 & 𝜃 − 1
𝐺 𝒓 =
∗
4𝜋
𝑟r

[2.9]

Where 𝜃 is defined as the angle between the local magnetization along B0 and the phase
at voxel r.
For magnetic susceptibility values 𝜒 << 1, one can approximate the relationship between
magnetization and susceptibility to be the following:
𝜇J 𝑀 𝒓 ≈ 𝐵J 𝜒 𝒓

[2.10]
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Therefore, the change in magnetic field at a specific point (r) can be expressed as follows:

∆𝐵(𝒓) = 𝐵J 𝜒 𝒓

∆𝐵(𝒓) = 𝐵J 𝜒 𝒓

𝐺 𝒓

3 𝑐𝑜𝑠 & 𝜃 − 1
4𝜋𝑟 r

[2.11 𝑎]

[2.11 𝑏]

While solving this equation may seem simple, it must be solved for every voxel in the
image. With the number of voxels approaching tens of millions, this becomes a
computationally expensive problem.
Fortunately, a convolution in image space can be expressed as a multiplication in Fourier
domain as such:

𝐹 ∆𝐵 𝑟

=𝐹 𝜒 𝑘

∗

1 𝑘v&
−
3 𝑘&

[2.12]

where 𝑘 & = 𝑘w& + 𝑘x& + 𝑘v& and kx, ky and kz, represent the distances along the x, y, and z
axes in the Fourier domain (or k-space). When k=0, which corresponds to the magic
angle where the numerator of the Green’s function in equation 2.11 is equal to 0
(𝜃 = 54.74º). This causes an ill-defined problem when attempting to solve for magnetic
susceptibility 𝜒 in the Fourier domain due to the division by zero that may lead to
streaking artifacts in the image reconstruction without optimization methods 10. A simple
optimization method could be to threshold values lower than a certain value to avoid
dividing by 0.
Attempting to overcome this ill-posed problem is an area of active research with many
algorithms currently proposed 10,20,21. These methods typically involve using prior
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information such as the edge information in the magnitude and phase and optimization
methods to estimate the susceptibility.

2.3.4.3

R2* Mapping

The measurement of the apparent transverse relaxation rate, R2*, is the final postprocessing step of multi-echo gradient echo sequences and the one used in all chapters of
this thesis. The simplest form of R2* mapping is done by performing a best fit line
through each of the acquired echoes assuming a mono-exponential decay, as shown in
equation 2.13:
∗

𝑆 𝑇𝐸 = 𝑆J 𝑒 z{|(}~ )

[2.13]

By acquiring S(TE) at known TE, solving for R2* appears to be rather trivial; however,
there are some confounding factors in the computation of R2*. The first confound is that
the acquired signal has superimposed noise from many sources that introduces error in
the acquired data; therefore, a line of best fit through the discrete time points is used to
model R2* decay. Throughout this thesis, a non-linear least squares method is used to
model the line of best fit for equation 2.13. Further complications may arise when fitting
data that approach the noise floor, although care is typically taken to avoid this situation
by excluding data that are below some multiple of the noise.
The second confound is the contribution of the macroscopic fields that could affect the
accurate measurement of R2* within the tissue. Several correction methods for the
compensation of the macroscopic field exists, such as voxel spread functions 22 or sinc
corrections 23. These corrections are most needed when the slice thickness is much
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greater than the in-plane resolution. When the slice becomes large, the macroscopic field
can no longer be assumed to be linear, and the dephasing within voxels is influenced by
the macroscopic field. These methods attempt to correct for the dephasing caused by the
macroscopic field. While these the voxel spread function described in [21] was used for
the experiment in this thesis, it was found that the slice thickness compared to in-plane
resolution (either 1:1 or 1:2) did not play a major contributing factor to the dephasing of
signal.

2.4

ME-GRE Application within this thesis

Together, the two previous chapters have given an appreciation of the role the vasculature
plays in glioma and subsequent imaging of treated gliomas. Additionally, multi-echo
gradient echo sequences have been shown to be susceptible to contributions of
deoxygenated blood that is present in tumors. The paramagnetic contributions of iron and
diamagnetic contributions of calcifications and myelin content will be investigated in the
next chapter, and non-contrast methods that could be expanded for clinical use will be
demonstrated.
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Chapter 3

3

R2* as a Marker for the Prediction of Radiation Necrosis
in a Rat Model
3.1

Introduction

There is long history of the use of external beam Radiation Therapy (RT) to treat many
forms of diagnosed brain neoplasms. While the ability to deliver conformal radiation to
the tumor has improved over the years, delivery of radiation is still associated with
significant doses to the adjacent brain parenchyma, and as such may cause side-effects in
various stages of the treatment 1. Side-effects are usually divided into acute, sub-acute,
and late-effects 1,2. Acute side-effects include brain encephalopathy secondary to
increased edema and tends to be associated with larger brain volume treatment or larger
dose per fraction treatments. Sub-acute or early-delayed side-effects are thought to be
caused by transient demyelination causing somnolence syndrome and is related largely to
the volume of brain radiated. In most cases, sub-acute side-effects either spontaneously
recover or are managed with the temporary use of steroids. Late-effects can be
irreversible and cause symptoms such as cognitive or neurological deficits. Among these
late-effects, Radiation Necrosis (RN) represents a form of focal brain injury and the risk
of RN is felt to be a complex interplay of total dose, dose per fraction, region, volume of
brain treated, and host factors 3.
The permanent effects of RN are one of the reasons guidelines on the total deposited
doses have been developed. Guidelines such as the Quantitative Analyses of Normal
Tissue Effects in the Clinic (QUANTEC) 4 have been developed to attempt to limit the
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incidence of RN. With the use of once-daily fractionation of less than 2.5 Gy/fraction, the
incidence of RN for partial brain radiotherapy has been reported at 5% and 10% with a
biologically effective prescription dose of 120 Gy3 or 150 Gy3, respectively. For
radiosurgery, the toxicity and risk of radiation necrosis increases with the target volume,
with increasing toxicity for a single fraction dose larger than 12 Gy and volumes larger
than 5-10 cm3. In addition to these guidelines, research has suggested reducing the
volume of brain irradiated and avoiding exposure to certain eloquent regions such as the
hippocampus, brainstem, and corpus callosum during RT should help to prevent
neurocognitive decline and/or focal deficits 4–7.
To optimize radiation treatment plans, improvements in radiotherapy techniques such as
image guidance, 3D conformal RT, Intensity Modulated Radiotherapy (IMRT), and
proton therapy have been shown to decrease radiation to the surrounding margins around
the planning treatment volume for certain brain tumors 8. These techniques allow
conformal RT of the neoplasm to reduce dose to surrounding brain and associated
structures while maintaining a sufficiently high dose to the planning treatment volume.
While efforts continue to optimize treatment plans, understanding the etiology of RN
could potentially aid in predicting or preventing its occurrence over the long-term.
Prognostic markers could allow for higher doses of RT to be delivered or toxicity to be
further reduced. The most prominent RN hypotheses supported over the past decades are
the vascular hypothesis 9–11 and the glial hypothesis11–13; however, neither fully explain
RN10,11.
The vascular hypothesis theorizes that RN is secondary to an ischemic event in the white
matter and is thought to result from small vessel obliterative vasculitis induced by
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radiation. Previous works have shown vessel wall thickening and vessel dilation 9,10 as
well as decreases in blood vessel density and length following radiation 14.
The glial hypothesis suggests that radiation directly causes damage to the white matter
precursor cells 15, which causes a demyelination process a few months to years following
RT. Studies have also shown that RN can be associated with apoptosis of
oligodendrocytes precursor 16 cells leading to the loss of mature oligodendrocytes and
damage to the astrocytes leading to a breakdown of the blood-brain barrier 17. It has been
shown that damage to endothelial cells may lead to increased cytokine production 18 and
elevated levels of vascular endothelial growth factor that lead to edema and necrosis 19–21.
Despite this work, the exact mechanism of RN is still uncertain and the potential for
prevention and/or ameliorating the effects of RN remains an area of active research. More
recently, a role for ongoing neuro-inflammatory processes has also been postulated 18.
While histological analysis provides a fundamental understanding into the cellular
processes at play, this information is limited in its ability to track the evolution of
radiation changes and requires invasive sampling, limiting its clinical application. In-vivo
imaging potentially allows continuous monitoring and could serve as a non-invasive
biomarker of tissue changes associated with radiation injury. The use of novel MRI
sequences and higher magnetic fields for MRIs has added new ways in which radiation
injury can be studied in pre-clinical and clinical settings. While traditional MRI
techniques are usually inadequate for proper differentiation of RN and tumor recurrence
22,23

, quantitative methods such as Diffusion Tensor Imaging 24,25, Magnetization Transfer

Contrast 26 and Chemical Exchange Saturation Transfer 27 have been shown to correlate
with RN and show promise in distinguishing between these entities.
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As radiation necrosis is thought to be vascular, glial, or inflammatory in nature, it can be
hypothesized that the use of higher field strength MRI and novel MRI sequences targeted
at imaging vascular changes would allow us to detect and track the development of
radiation injury in a pre-clinical model. To this end, this experiment sought to monitor
animals receiving high dose partial brain radiation using imaging at a regular intervals
using a 9.4T MRI scanner and performed quantitative and qualitative imaging over the
course of 28 weeks. The techniques used were Susceptibility-Weighted Imaging (SWI)
and apparent transverse relaxation rate (R2*) mapping, which have previously shown to
be sensitive to venous vasculature 28 and tissue microstructure such as iron or myelin
content 29,30. These techniques were used in conjunction with the current gold-standard
for imaging radiation necrosis, gadolinium-enhancing T1 MRI.

3.2
3.2.1

Materials and Methods
Rat Selection and Imaging Time Points

All experiments were conducted with the approval of the Animal Use Subcommittee
protocol at the University of Western Ontario. Male Fischer 344 (strain code 002) rats
from Charles River were obtained at an age of approximately eight weeks and a weight
range of 150-170 grams. Upon arrival, rats were acclimatized for three days and were
then scanned for a baseline (week 0) 3-5 days after arrival at the animal facility. Rats
were kept in a conventional housing room with a 12 hour (7am/7pm) light cycle. Seven to
ten days after arrival, rats were irradiated using the methods described below. Rats were
imaged on the MRI one week and two weeks after receiving their radiation and
subsequently every 2-4 weeks until 28 weeks after irradiation at which point they were
sacrificed. Some rats were sacrificed at earlier times points for histology or due to illness
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(typically a 15-20% weight loss). Rats were divided into three cohorts; 1) micro-CT
radiation (n=8), 2) x-Rad 225 radiation (n=10), 3) control (n=4).

3.2.2

Magnetic Resonance Imaging

Magnetic resonance imaging was performed on an Agilent 9.4 T horizontal small bore
animal scanner. Rats were anesthetized with isofluorane combined with medical air (4%
induction for 2-4 minutes, 1.5-2% maintenance). A custom-built two-channel head
conformal transceive RF coil was used for imaging. Rats were placed on a stereotactic
frame and secured with ear bars for the duration of the scan (1.5-2 hours). The acquisition
protocol consisted of a bSSFP sequence (TR 5.0 ms / TE 2.5 ms, matrix size
250x180x180, FOV 43.8 mm x 31.5 mm x 31.5mm, scan time 11 minutes) and
3 averages of a 7 or 8 echo multi-echo gradient echo sequence (FA 10°, TR 30ms, TE 2.5
ms, ESP 2.7ms - 3.0ms, matrix size 250x180x180, FOV 43.8 mm x 31.5 mm x 31.5mm,
scan time 16 minutes). At later time points, a T2-weighted fast spin-echo sequence was
also acquired. Gadolinium T1 images were acquired at 12, 17, and 24 weeks using a
similar anesthetization protocol. A T1-weighted gradient echo (FA 30°, TR 45 ms, TE 2.5
ms, matrix size 130x90x90, FOV 43.8 mm x 31.5 mm x 31.5mm, scan time 6 minutes)
was acquired approximately 2 hours following an intraperitoneal injection of the
gadolinium contrast agent Magnevist (1mL/100g). It should be noted that the week 8 time
point for control rats had to be discarded due to a malfunction of the gradient coil chiller
causing unreliable data.
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3.2.3

Partial Brain Radiation

The first irradiation was performed on a micro-CT irradiator 31. A schematic of the
delivered radiation plan is shown in Figure 3.1. The treatment plan consisted of 10-30 Gy
delivered to the right hemisphere using a 150 kVp beam. Dose step gradients were
performed using the micro-CT jaws as shown in Figure 3.1. The delivered dose rate was
calculated to be 30 cGy/min; however, due to heating of the x-ray tube radiation delivery
had to be done in blocks allowing for cool-down over the course of radiation delivery.
The effective dose rate (delivered dose / total time) was calculated to be approximately
10-15 cGy/min depending on total delivered dose when delivered over the course of three
hours. The micro-CT had imaging capabilities allowing us to confirm the dose delivery to
the proper area.

Figure 3.1 Illustrative dose plan superimposed on bSSFP image. On the left is a
schematic dose distribution for animals irradiated on the xRad-225 platform up to
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40 Gy (n=10). On the right is a schematic of the dose distribution of the micro-CT
platform. The red box indicates a dose of 30 Gy, the yellow box a dose of 20 Gy and
green box a dose of 10 Gy.
The second platform used was an IGRT x-Rad 225 irradiation device. Dose rate was
calculated to be approximately 2.3 Gy/min and the entire dose was delivered over 17.5
minutes using a 225 kVp beam. This resulted in a total dose of 40 Gy to the right half of
the brain, delivered by a single appositional field directed superior to inferior through the
brain. Dose planning was performed using custom-built Monte-Carlo analysis.
Additionally, the x-Rad 225 had image localization allowing confirmation of the dose
delivery to the right hemisphere. A schematic dose plan is also shown in Figure 3.1 (a).
In both cases, a dose deposition gradient differential of approximately 5 Gy over the
superior-inferior direction due to the kV-beam was calculated. Finally, control rats
underwent sham radiation by being anesthetized for 15 minutes using similar conditions
for irradiated rats.

Figure 3.2 Illustrative timeline of protocol
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3.2.4

Image Processing and Segmentation for Image Analysis

Manual segmentation was performed using the ITK-Snap software 32. Any radiationinduced lesions, both hippocampi, and right hemispheric white matter were manually
segmented. Lesions were segmented by using co-registered images of the gadoliniumenhancing T1 image and the average image of all echoes. With the mutual information
from both images, it was easier to exclude the CSF, striatum, and blood vessels
surrounding the gadolinium-enhancing lesion.
Using the Oxford Centre for Functional MRI of the Brain Linear Image Registration Tool
registration toolbox (FSL FLIRT), the segmented radiation necrosis region of interest was
retrospectively overlayed on earlier time point images with registration errors no greater
than 1-2 voxels. Proper registration was confirmed by using the contralateral
internal/external capsule junction and anterior corpus callosum as a landmark. These
retrospectively applied regions were used to determine if there were vascular changes
detected with the R2*and SWI images at earlier time points that preceded the onset of
frank necrosis.
Both left and right hippocampus were manually segmented, avoiding areas that were
adjacent to the air-tissue interface. Finally, the white matter tracts (which included the
corpus callosum and the internal and external capsule) were manually segmented. In all
segmentation, the Paxinos atlas 33 was used as a guide. Care was taken to minimize
partial volume effects.
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3.2.5

SWI Processing

Before SWI processing, a four slice sliding window (convolution filter) was applied
along the direction of the magnetic field, which was also the direction of the slice
selection, as described by Haacke 34. Following this step, high-pass filtering using a
7 mm Gaussian filter was applied and a weighted non-linear least squares fit through each
echo was used to obtain a local frequency shift map 35. A cutoff frequency value of 17 Hz
was applied to get a frequency mask that was multiplied four times into the magnitude
data. Final SWI maps were then minimum intensity projected through 5 slices (875 µm).

3.2.6

Statistical Analysis

Statistical analysis was performed using Prism version 6.0h. The statistical analysis
compared irradiated rats to control rats using a repeated measures multiple comparison
two-way ANOVA using Sidak correction for multiple comparisons.

3.2.7

Histology

Following the last time point scan, rats were sacrificed by increasing the level of
isofluorane to 5% until there was no more response to stimuli and perfused using an
intracardiac catheter with a saline/heparin flush followed by 10% formalin solution. The
excised brain was placed in a 10% formalin solution for at least seven days before being
processed and blocked.
Standard tissue staining was performed at the adjacent hospital’s pathology laboratory.
Tissues were block and stained with Hematoxylin and Eosin (H&E) and Luxol Fast Blue
(LFB). H&E is a histology stain that is commonly used for nuclei (stained by the
hematoxylin and viewed as blue or purple) as well as cytoplasm and erythrocytes (stained

55

by eosin and viewed as red or cherry red, respectively). LFB is a basic myelin stain used
to detect myelination within the central nervous system. Microscopy was performed
using an Aperio digital pathology slide scanner.

3.3
3.3.1

Results
Animal Behavior and weight

Animals irradiated using the micro-CT exhibited similar growth patterns compared to
control rats. Animals irradiated using the xRad-225 exhibited a slower weight gain
following irradiation; however, the weight gain was constant, and the animal’s weight did
not vary by more than 15% compared to control. The mean weights and standard
deviations are shown in Figure 3.3.
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Figure 3.3 Graph of weight distributions with mean and standard deviations for
each time point. Data points with no error bar indicate standard deviation smaller
than the point.
Rats irradiated with the xRad-225 exhibited a hunched appearance towards the end of the
experiments, but they did not exhibit other symptoms. The ipsilateral front incisors had to
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be cut approximately 16 weeks following treatment for rats treated with the xRad-225
and subsequently trimmed every 2-4 weeks as necessary.
Only three rats that were irradiated with the xRad-225 survived until week 24. Originally,
four rats were planned to be sacrificed along the timeline for histology, and three rats had
to be sacrificed at earlier time points than planned due to weight loss. The specific source
of weight-loss was due to refusal of water, food, or soft-mash in two rats, while one
suffered from exsanguination from the ear on the irradiated side.

3.3.2

SWI and Gadolinium MRI

Throughout the study, there were no qualitative changes observed on the processed SWI
images.
Gadolinium MRIs were performed on rats irradiated using the micro-CT before being
sacrificed, and no rats demonstrated visible morphological changes. For rats irradiated
with the xRad-225, morphological changes on Gadolinium MRI were apparent on all
imaging sequences at week 24 as illustrated in Figure 3.4.
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Figure 3.4 Radiation necrosis developed at the internal and external capsule, as
shown by T1-gadolinium enhancing MRI (a) and increased R2* (b).
The enhancing gadolinium lesion on MRI can be attributed to the breakdown of the
blood-brain barrier due to radiation necrosis; this was subsequently confirmed by
histologic examination (Figures 3.5 and 3.6).

3.3.3

H&E and Luxol Fast Blue Histology

While histology was performed on all three rat cohorts (Control, Micro-CT irradiated,
and xRad-225 irradiated), only rats irradiated on the xRad-225 exhibited changes at later
weeks as shown in Figures 3.5, 3.6 and 3.7. The Luxol Fast Blue stain shows
hypointensities on Figure 3.5 and 3.6 indicated a loss of myelin content. The H&E stain
also shows hypointensities indicating possible loss of tissue or disruption of the collagen.
Vessel dilation was also apparent as early as week 16.
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Figure 3.5 H&E stain (a) and LFB stain (b) demonstrating white matter necrosis
within the internal capsule within the black box. Zoomed image of Internal Capsule
(C) shows vessel dilation and hypointensity. Panels A and B are at 1x magnification;
panel C is at 20x magnification.
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Figure 3.6 Combined H&E with LFB stain at week 20. Arrow indicates area of
demyelination at the external capsule shown as hypointense purple.
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Figure 3.7 H&E slide for brain at week 16. Top is 1X magnification and bottom is
20X magnification
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3.3.4

Differences in R2*

Rats irradiated on the micro-CT did not develop imaging evidence of necrosis nor were
any statistically significant changes in R2* in the segmented normal tissue structures
detected. The remaining results pertain to those rats irradiated on the xRad-225 platform
or controls.
The raw R2* values within the region of eventual radiation necrosis in the three rats
irradiated on the xRad-225 who survived until week 24 appear in Figure 3.8. An upward
trend of R2* appears around the Week 14 time point, which was 8-10 weeks before any
morphological changes appeared on the gadolinium-enhancing T1 or bSSFP.
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Figure 3.8 Measured R2* within lesion for each rat. An increasing trend of R2* is
apparent as early as week 14.
The number of rats used for analysis in Figures 3.9, 3.10, 3.11, and 3.12 are provided in
Table 3.1.
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Table 3.1 Number of rats used in analysis
Week #
0

Number of Control
rats
4

Number of Irradiated Reason for loss of
rats
Irradiated Rat
10
X

1

4

10

X

4

4

8

12

4

5

16
20
24

4
4
4

5
4
3

1 Histology
1 Weight Loss
1 Histology
1 Weight Loss
1 Exsanguination
from ear
X
1 Histology
1 Histology

Within the ipsilateral hippocampus, a statistically significant mean difference of R2*
between control and irradiated rats occurred at week 12 (95% CI: 0.1-2.4 s-1, P < 0.05)
with significance at each subsequent time point as shown in Figure 3.9. In addition to
differences between irradiated and control rats, a statistically significant mean difference
between the ipsilateral and contralateral irradiated hippocampi within irradiated rats is
evident at week 20 (95% CI: 0.5-3.0 s-1, P < 0.01), as shown in Figure 3.10. There was no
statistical significance for the mean difference between the left hippocampus in both
irradiated and control rats, although a trend of increased R2* in the irradiated contralateral
hippocampus is readily apparent as shown in Figure 3.11.
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Figure 3.9 Mean difference of R2* between irradiated and control right
hippocampus, error bars represent 95% confidence intervals, significance is
represented by * P < 0.05, ** P < 0.01, *** P < 0.001.

Figure 3.10 Mean difference of R2* between irradiated ipsilateral and contralateral
hippocampus, error bars represent 95% confidence intervals, significance is
represented by * P < 0.05, ** P < 0.01.
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Figure 3.11 Mean difference of R2* between contralateral and control left
hippocampus, error bars represent 95% confidence intervals. While there are no
significant results, a weak trend of increasing R2* is apparent.
Within white matter tracts significant changes to the R2* between ipsilateral radiated and
control white matter tracts were not apparent; however, a steady increase in the mean
difference over time was observed as shown in Figure 3.12.
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Figure 3.12 Mean difference of R2* between irradiated and control white matter
tracts, error bars represent 95% confidence intervals. While there are no significant
results, a trend of increasing R2* is apparent.

3.4

Discussion

This study has demonstrated a model in which increases of R2* in white matter tracts and
hippocampus precede the morphological appearance of necrosis on gadolinium T1weighted imaging and bSSFP. In this specific cohort of rats, the R2* consistently
increased in the external and internal capsule over time. This finding appears to be at
odds with the vascular hypothesis, as an ischemic event in the irradiated area should be
associated with a decreased R2* due to lower blood volume and blood flow in the region.
Thus, the mechanism of RN may be more complex than radiation induced vascular injury
and occlusion leading to ischemia. Increases in R2* could be indicative of vascular effects
from neuroinflammation or vascular changes other than occlusion at the lesion site.
Should small vessels be obliterated at the radiation site, as suggested by the vascular
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hypothesis, residual by-products of vasculature (such as de-oxygenated hemoglobin)
would increase the R2*. In fact, on histologic examination vascular dilation in the region
where radiation necrosis was detected can be noted as early as week 16 as shown in
figure 3.7, suggesting vascular effects are part of the mechanism, and further research is
needed to relate changes on R2* to histology. If changes are happening at the capillary and
small venules level, it is possible that the BOLD effect 36 of larger vessels dominate
within a voxel due to the larger venules remaining intact as previously shown by
histology 37, reducing the sensitivity to ischemic events in the capillaries. Additionally, it
has been suggested small vessel changes occur in the hours or days following RT 11 and
there are transient/variable changes in blood flow that may not have been detected with
isolated imaging sessions.
While the data did not find any statistically significant changes in R2* within the white
matter tracts, a trend towards an increase in R2* in white matter regions is apparent. Interweek and inter-animal R2* differences of 1.5 s-1 were measured, which were attributed to
partial volume during the segmentation. In most areas, the white matter tract was no
wider than 2-3 voxels making proper segmentation difficult. It is possible that in humans,
whose white matter tracts are larger and can span more voxels, longitudinal differences in
R2* would be less sensitive to segmentation errors. The measured increase in R2* could be
a neuroinflammatory mechanism in which there is increased iron content due to the
presence of macrophages within the white matter tract. Further histologic examinations of
the treated animals and examination among larger cohorts of animals would be needed to
confirm this hypothesis.
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The statistically significant increases in R2* within the hippocampus also support
neuroinflammatory mechanisms within the hippocampus that have recently been
suggested as mediating cognitive changes following radiation 38. The decreased mean
difference trend at week 1 could be supportive of decreased deoxygenated blood, again
supporting the notion that RN is a complex process that evolves over time. The nonstatistically significant trend of increased R2* within unirradiated hippocampus could be
due to the high interconnectivity of the hippocampi along the corpus callosum. Larger
cohorts and further immunohistochemistry investigations are necessary to identify the
cause of this trend.
Of interest, the choice of radiation platform influenced the development of radiation
injury. It is possible that the lower dose 39 or lower dose rate associated with the microCT (maximum 30 Gy at 30 cGy/min) compared to the xRAD-225 accounted for lack of
RN lesions noted. Specifically, animals irradiated on the micro-CT at an effective dose
rate of 3-5 mGy/min to 30 Gy partial brain volume did not develop any necrosis at 28
weeks after radiation, at which point they were sacrificed per the ethics protocol. It
cannot be refuted that necrosis may have developed at a time point later than 28 weeks;
however, this time point represents approximately 15-25% of the rats’ expected lifetime,
and previous established models of necrosis in rat occur between 18-26 weeks following
RT 25,40,41. In comparison, all animals irradiated on the xRAD-225 at 2.3 Gy/min to 40 Gy
partial brain volume developed RN lesions. Thus, future studies examining RN in preclinical models should take into account dose rate as a potential confounding factor are
warranted 42,43.
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This study provides motivation for further research on the R2* dependence on RN, and
further evaluations that correlate with histology and immunohistochemistry could provide
further insight into the mechanisms increasing R2*. Given the small sample size of
animals with RN, further validation of the findings in larger cohorts and alternate preclinical models are necessary. Another extension of this work would be to examine the
utility of this imaging in pre-clinical models of glioma. In particular, these models could
be used to explore whether RN can be differentiated from residual tumor using R2*.

3.5

Conclusions

In a pre-clinical model of RN, R2* acquired at 9.4T was able to detect early parenchymal
changes that preceded the development of overt necrotic lesions. Variable temporal and
spatial patterns of R2* suggest RN is a complex interplay between neuroinflammation and
vascular and glial injury.
This chapter provided motivation for the future experiments within this thesis as data
obtained suggest this technique is highly sensitive to increases in the vasculature and
potentially neuroinflammatory components following RT. The next chapters will
investigate whether changes in the vasculature are detectable in humans in the sub-acute
and long-term time periods following therapy for both benign and malignant glioma.
Chapter 4 will investigate vascular effects within the high dose regions of benign
neoplasms and the subsequent effects it could have on the long-term health of these
patients. Finally, Chapter 5 will investigate whether the differences in R2* as shown in
this chapter can be applied to non-specific post-treatment imaging changes following
chemoradiotherapy to differentiate between glioma recurrence and treatment effect.
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Chapter 4

4

Assessing Vasculature and Microstructural Changes in
Low-Grade and Benign Brain Tumors Using Ultra-High
Field MRI Techniques
4.1

Introduction

External beam radiotherapy (RT) is commonly employed as a treatment for many brain
neoplasms. In benign and low-grade neoplasms (meningiomas, neuromas, low-grade
gliomas), safe maximal surgical resection combined with RT is usually the standard of
care. The prescribed dose is typically a course of 54-60 Gy in 30 fractions using
conformal delivery with techniques such as intensity modulated radiation therapy. These
dose plans attempt to follow specific guidelines such as QUANTEC to limit dose to
radiosensitive areas such as the uninvolved brain, brain stem, optic nerve, and optic
chiasm 1, as well as the hippocampus that is known for its role in neurogenesis 2,3. Due to
the infiltrative nature of some neoplasms such as low-grade gliomas or the proximity of
tumors to normal brain in other neoplasms, even conformal radiation techniques can
result in some volumes of normal tissue receiving radiation. The dose delivered to the
normal brain can potentially cause long-term effects later in the patient’s life.
Following RT, there are numerous reports of clinical sequela that are classified into
acute, early-delayed, or late-effects 4. Acute and early-delayed side-effects are usually
temporary and resolve spontaneously with minimal treatment or steroids. Late-effects are
typically much more severe as they cause permanent changes to the brain parenchyma
that include radiation necrosis (RN), cavernous angiomas, and microbleeds 4 resulting in
ongoing neurologic deficits.
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RN is a side-effect that may present itself a few years following RT; however, it can
occur as early as six months and as late as ten years following RT. In some patients,
regions of RN may be small and do not produce symptoms. In others, progressive RN can
be seen with significant effects on the patient's quality of life 5. Symptoms ranging from
headaches and drowsiness to memory loss, seizures, and focal deficits have been
documented. Treatments of RN range from observation to steroids or anti-angiogenic
agents 6. In some patients, surgical resection is required to debulk necrotic areas to
alleviate symptoms.
The exact cause and time-course of RN is not fully understood, but the two main
hypotheses developed in the past 50 years are related to vascular and glial damage 4. The
vascular hypothesis suggests that radiation necrosis is secondary to an ischemic event,
while the glial hypothesis suggests that white matter precursor cells are damaged during
RT. Recently, the role that the immune response plays following RT has been
documented 7,8. The theory proposes that neuroinflammation could be another
mechanism contributing to the development of RN.
In addition to frank RN, microbleeds that occur at later time-points and are detected on
imaging following RT are a recent discovery 9,10. Microbleeds may serve as a marker for
future vascular disease such as stroke 11. Not only do microbleeds indicate that more
serious diseases could occur in the future, but the patient could be put at risk of more
significant intracranial bleeding if started on anticoagulants 12. Techniques such as
Susceptibility-Weighted Imaging (SWI) are becoming more prominent with higher
magnetic field strengths available clinically (3T) or for research (>7T). These techniques
make locating microbleeds increasingly easier, as the spatial resolution can be increased
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with higher magnetic fields and the paramagnetic effect of the hemosiderin deposit
increases linearly with field strength. Consequently, the increased resolution can also lead
to false-positives in microbleed detection as small venous vasculature that runs parallel to
the magnetic field can be misinterpreted as microbleeds. SWI, Quantitative Susceptibility
Mapping (QSM) and apparent transverse relaxation (R2*) have been previously shown to
be extremely sensitive to the vasculature and hemosiderin rich microbleeds 13,14. These
techniques are also sensitive to white matter lesions, as shown in various multiple
sclerosis (MS) studies 15,16. Previous work from Raichenbaich et al. 17 estimates that these
techniques are sensitive to venous vasculature of approximately 100-200 micrometers in
diameter.
Among brain tumor patients, most studies to date have investigated microbleeds and
radiation necrosis among patients who have high-grade neoplasms 18,19; however, longterm RN studies in this patient population may be less feasible due to the shortened life
expectancy for most patients with malignant glioma. Additionally, these studies involve
patients who are treated with chemotherapy, which has been shown potentially to
influence the number of microbleeds present in the brain 10,20 and may confound the
estimates of microbleeds due to radiation alone.
This research study presents initial results that focus on imaging the microvasculature and
microbleeds using techniques such SWI, QSM, and R2* on patients treated for benign or
low-grade neoplasms. These patients have a longer overall survival (OS) following
successful treatment and as such are at higher risk of eventually experiencing delayed
adverse RT effects. Thus, it is hypothesized that SWI, QSM, and R2* may be a useful
imaging technique to detect late radiation changes among this patient population and in
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doing so, identify patients who might be at risk of longer-term sequelae of their treatment
(cognitive effects or focal brain injury).

4.2
4.2.1

Materials and Methods
Patient Recruitment

The study was approved by the Human Subjects Research Ethics Board of the University
of Western Ontario. Ten patients (two males, eight females) were recruited from the
London Regional Cancer Program (LRCP) and were screened for eligibility by the
treating radiation oncologist. Eligibility requirements included patients who were over 18
years old, Karnofsky Performance Status > 60, and who were treated for a benign or
WHO Grade 1 or 2 brain neoplasm within 12-36 months of their recruitment for the
study. Treatments for their neoplasms could have included surgical resection followed by
radiotherapy or primary radiotherapy alone. As per protocol, patients underwent an initial
imaging session at the time of enrollment and a second session 12-24 months later to
detect any change in imaging features.

4.2.2

MRI

Patients were scanned on a 7T MRI at the Robarts Research Institute in London, Ontario.
The first MRI for all patients was performed on an Agilent/Siemens 7T MRI with a 15
channel transmit / 31 receive channel coil. Three of the patients had their second carried
out after a major upgrade to a Siemens 7T Magnetom Step 2.3 MRI with an 8 channel
transmit / 32 receive channel coil while three patients had both MRIs on the Agilent
scanner. An anatomical T1-weighted image was performed (Agilent: MPRAGE, 1 mm
isotropic voxel, scan time 5 min 45 seconds / Siemens: MP2RAGE, 0.8 mm isotropic
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voxels scan time 8 minutes 26 seconds) and a CSF attenuated MPFLAIR (Agilent: 1 mm
isotropic resolution, scan time 12 minutes 42 seconds, SEIMENS: not acquired) was
acquired for registration to clinical scans. A multi-echo gradient echo (Agilent: Multiecho gradient echo, 1 mm in-plane resolution, 1.5 mm slices, TR=40 ms, TE=2.4 ms,
ESP=3.3 ms, echoes=6, FA 13° GRAPPA 2.1 / Siemens: Multi-echo gradient echo, 1 mm
in-plane resolution, 1.5 mm slices, TR=40 ms, TE=4.9 ms, ESP=4.5 ms, echoes=6, FA
13°, GRAPPA 2) was acquired.

4.2.3

Post Processing

The multi-echo gradient echo data set was acquired and post-processed into SWI, R2* and
QSM maps using in-house software. The implementation of QSM used a pre-conjugate
gradient method and was compared to QSM using the MEDI toolbox 21; however, the
data from the Agilent scanner was not optimized for MEDI processing. R2* was computed
using a non-linear least squares mono-exponential fit with a voxel spread function for
correction 22. An 11-mm Gaussian high-pass filter was used to filter the phase and the
phase was fit with respect to TE using a weighted non-linear least squares function to
calculate the local frequency shift map. A frequency-mask of 15 Hz was then applied to
an average magnitude image from all echoes to create SWI. Finally, MATLAB (The
MathWorks Inc. Natick, MA) was used to create a minimum intensity projection image
(mIP) through 7 mm (7 slices) of the SWI.

81

4.2.4

Dose Plan Overlay

Treatment dose plan, as well as planning CT and MRIs, were retrieved from the LRCP
and were registered to the research MRI using FSL’s FLIRT toolbox 23. CERR 24 was
used to export the dose plan.

4.2.5

Microbleed counts, Vasculature and White Matter
Abnormalities

Images (SWI, MPRAGE, and FLAIR) were reviewed by a neuroradiologist blinded to the
history of the patient. The neuroradiologist was asked to count the microbleeds on all
images and assess for vasculature and white matter abnormalities.
Once identified, the microbleeds were segmented on the SWI using ITK-snap 25 for
analysis using R2* and QSM.

4.3
4.3.1

Results
Clinical Findings

Ten patients consented to imaging and were enrolled in the study. A full description of
their cases, treatment, and current clinical status is provided in Table 4.1. A mini-mental
status exam (MMSE) was performed at the first visit and a mean score of 29/30 ± 0.9
indicated patients were grossly cognitively intact at assessment. Patients were imaged at a
mean of 26.7 ±7.5 months following their treatment, and six of ten patients returned for a
second MRI between 12-24 months (17.3 ± 7.3) following their first MRI. Four patients
did not return for this second scan. Two patients became ill for unrelated health reasons;
one patient opted not to return for their second research scan and one patient’s low-grade
glioma evolved into a malignant glioma, and their clinical condition precluded reimaging.
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Table 4.1 Patient Clinical Status. DNR indicates did not return, V1 indicates Visit 1,
V2 indicates Visit 2.
Patient/
Sex

Age at time of
treatment

Diagnosis

RX
(Gy/Fraction)

Time btw
RT-V1/
Time btw
V1-V2
(months)

Current Clinical Status

1 (F)

29

Surgery +
60/30

30/11

2 (F)

32

WHO Gr. 2
Meningioma
Rt. Sphenoid Wing
Midline Recurrent
Atypical Meningioma

Surgery +
66/30

14/DNR

3 (F)

57

WHO Gr. 1
Meningioma occipital
region

Surgery +
54/30

30/DNR

4 (F)

57

Craniopharyngioma

54/30

13/14

5 (F)

57

Left acoustic neuroma
and posterior fossa
meningioma

Surgery +
54/30

23/10

6 (F)

63

Meningioma of the
left sphenoid wing

Surgery +
66/30

17/22

7 (F)

55

Brain Stem Glioma
WHO Gr. 1

54/30

23/22

8 (M)

33

Recurrent
Meningioma of base
of skull

54/30

20/12

9 (M)

50

Left posterior fossa
meningioma

60/30

14/DNR

10 (F)

45

Left temporal lobe
Mixed
oligoastrocytoma
WHO Gr. 2

60/30

14/DNR

Employed Part-time. Aug 2015
MRI stable post surg. Changes
and post-RT WM changes.
Stable MRI findings no
evidence of progression, stable
residual masses next to treated
area.
Asymptomatic from
meningioma, no evidence of
recurrence, unrelated thyroid
treatment.
Reduction in size of
craniopharyngioma,
stable FLAIR hyperintensities
in the hippocampi bilaterally.
Working full time, occasional
dizziness bending over or
working on ladders. Stable
right cerebellopontine angle
meningioma.
Retired, well with no
symptoms and no evidence of
progression/recurrence on
MRI.
Elevated prolactin due to
pituitary dysfunction, possible
treatment effect. Some facial
twitching similar to initial
presentation of tumor, but not
requiring treatment. Near
complete response.
Working full time with mild
fatigue. Short term memory
problems, history of WBRT for
ALL in 1982.
Stable on follow-up imaging
with decreasing enhancement
in cerebellum.
Developed glioblastoma, no
follow-up.
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4.3.2
4.3.2.1

Imaging Findings
Venous Vasculature

On a whole, no gross abnormalities or venous vessel density discrepancies were observed
on the SWI. One patient (Patient 8) had a cavernous angioma that had been previously
detected on conventional MRI before enrollment in this study.

4.3.2.2

Microbleeds

Six of ten patients had microbleeds on the post radiation imaging. All microbleeds
occurred in areas of high dose (>45 Gy). Some microbleeds resolved between the initial
and follow-up scan. The full list of microbleeds is reported in Table 4.2. In all patients,
microbleeds had an R2* greater than 80 s-1 and QSM values lower than -250 ppb. Most
microbleeds had a halo artifact as shown in Figure 4.1 that aided in their detection.
Table 4.2 Microbleed count per visit.
Patient

Visit 1
Microbleeds

Visit 2
Microbleeds

New
Microbleeds

Resolved
Microbleeds

1

7

4

2

5

2

5

X

Did not return

Did not return

3

4

X

Did not return

Did not return

4

0

0

0

0

5

2

2

0

0

6

2

0

0

2

7

0

0

0

0

8

0

0

0

0

9

1

X

Did not return

Did not return

10

5

X

Did not return

Did not return
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Figure 4.1 Illustration of microbleeds (white arrow) for Patient 1 in optic tract’s
(top row) and lobar microbleed (bottom row). The mIP SWI image shows venous
vasculature in areas of high dose similar to the contralateral area.

4.3.2.3

White Matter Abnormalities

Three patients had periventricular or lobar lesions on their MPRAGE and FLAIR images
in the mid (>30 Gy) to high dose (>45 Gy) regions consistent with white matter changes
reported after RT 26,27. Upon examination of the post-processed QSM and R2* images, the
periventricular white matter lesions have less volume than on FLAIR and MRPAGE
(Figures 4.2 and 4.3), and this has been documented previously in literature as FLAIR
tends to overestimate the amount of white matter change especially in the periventricular
lesions 28. The lesions’ low R2* strongly suggests demyelination, but the patients in this
series were asymptomatic. Therefore, the clinical relevance and future clinical course of
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these white matter findings is unknown, although others have reported the presence of
asymptomatic white matter changes on long-term follow-up after radiotherapy. An
interesting observation is that these lesions have penetrating veins, as can be seen in
Figure 4.2, 4.3, and 4.4 as is often seen in MS.

Figure 4.2 Patient 2 showing areas of residual tumors near midline as well as white
matter damage in high dose regions. Venous vasculature is apparent in damaged
white matter on R2* and SWI as shown by the white arrows.

86

Figure 4.3 Patient 3 showing periventricular lesions that appear to be venocentric as
indicated by the white arrow on FLAIR (hyperintense) and R2* (hypointense).
Adjoining to the lesion, a microbleed is evident on R2*, which is indicated by a
yellow arrow on QSM

Figure 4.4 Zoom in on Figure 4.3, where the microbleed is apparent on SWI and R2*
and the venocentric lesion is indicated with white arrow.
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4.3.2.4

Current Clinical Status

As shown in Table 4.1, most patients who enrolled in this study are clinically stable
following treatment for their neoplasms. Aside from Patient 10, who developed a
glioblastoma, their symptoms are not directly related to their diagnosis or treatment.

4.4

Discussion

It is believed that this is the first study that investigates vasculature and white matter in
patients who have been treated for low-grade or benign neoplasms with radiation and
surgery only. The potentially long survival of this patient population post-treatment
increases the chance that they may experience late radiation side-effects compared to
patients with higher grade lesions. Imaging biomarkers that could identify patients at risk
of delayed radiation sequelae could be useful in this patient population to refine radiation
delivery techniques and to explore mitigating strategies like pharmacologic interventions
29

.

The main focus of this study was to determine what effect RT would have on the normal
parenchyma during the late-effect time window (3-5 years after therapy). Gross
abnormalities were not expected, as these patients were clinically stable and on
conventional imaging, but it was hypothesized that it could be possible to detect
subclinical lesions in the brain receiving significant doses of radiotherapy. The detection
of these subclinical lesions may be useful for future time points should these subclinical
lesions develop into necrosis. Therefore, this warrants further studies of a longer period
for this patient subset. It is known that microbleeds appeared in patients treated with
chemotherapy or radiotherapy for high-grade neoplasms 10. Additionally, Liu et al.
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demonstrated the ability to distinguish microbleeds from venous vasculature using
quantitative methods [17]. Therefore, an investigation into the occurrence of microbleeds
and demyelinating lesions as a potential imaging biomarker of late radiation effects in
patients treated for low-grade brain neoplasms was performed.
In this cohort, six of ten patients showed microbleeds within the high dose regions and in
five of six patients, no microbleeds were observed outside the high dose region. Longterm follow-up is required to correlate with clinical endpoints like future vascular
incidents or cognitive side-effects to determine if microbleed monitoring could be of
significant importance in these patients.
Although these patients do not have the number of microbleeds as shown in other studies
of high-grade neoplasms, the appearance of microbleeds is indicative of endothelial
damage within the high dose region. This suggests the importance of long-term
monitoring in this low-grade cohort as these patients could be at a higher potential for
symptomatic vascular or cognitive changes later in life 30,31. The appearance of
microbleeds could also indicate that further studies are required to look at the effect of
anticoagulants. Certain studies have already shown that appearance of microbleeds in
other disease states could be a contraindication for use of anticoagulants 32 and these
findings suggest strategies attempting to limit radiation injury through the use of antiplatelet agents or anti-coagulation in this patient population should be evaluated
cautiously.
Further to venous vasculature being present in high dose regions, veins within
demyelinated lesions in the area of high doses can be observed. This is a common finding
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in MS and acute disseminate encephalomyelitis 33. The white matter lesions have
previously been reported in the past 26,27,34 with reports of cognitive decline. A recent
communication has shown that a 43-year-old patient developed similar MS-type lesions
following RT 35. In MS, these lesions have been shown to have an immune response that
could be indicative of neuroinflammation. The ability to show that these lesions have
venules running through them suggests further studies are warranted to test this
hypothesis of neuroinflammation as a mediator of late radiation effects. Supporting this
finding was the detection of FLAIR hyperintensities coupled with the low R2* values that
would indicate demyelination. Neuroinflammation as a mediator of radiation late cerebral
effects and as a potential therapeutic target is an area of active investigation 29 and these
findings suggest imaging biomarkers like SWI and R2* might be useful tools for noninvasive monitoring of neuro-inflammatory processes.
This method also corroborates other results that show that the use of multi-echo gradient
echo can be of practical importance in the post-treatment monitoring of patients. In
addition to SWI and R2*, QSM can be used to differentiate between small veins and
microbleeds. The halo effect and large susceptibility value of the microbleed on QSM is
something that could lead to reduced burden for neuroradiologists when detecting
microbleeds through the use of automated methods. Additionally, the high R2* can help
distinguish microbleeds and small venules that have much lower R2* values (20-40 s-1).
A limitation of this study is the limited number of participants and inability to acquire
follow-up imaging for all patients. This preliminary experience illustrates the feasibility
of the technique in this population and suggests a study of larger cohorts of patients with
this imaging technique may be warranted.
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Another limitation of SWI techniques, in general, is that titanium clips used following
surgery cause blooming artifacts on post-processed images. The artifacts are caused by
the magnetic field perturbation caused by these clips and causes the signal to decay at a
much higher rate, causing more issues with lengthened TE. Finally, SWI is limited in its
ability to view the arterioles; however, Bian et al. 36 have shown that arteries and veins
can be imaged in the same acquisition. This method also can decrease false-positives and
to improve microbleed detection. This method would also be beneficial in observing
damage to the arterioles.

4.5

Conclusions

This chapter presented a preliminary study examining the long-term effects that radiation
therapy has on patients treated for benign or low-grade neoplasms. It was demonstrated
that these patients are susceptible to microbleeds as well as demyelinating lesions. This
study suggests this subset of patients requires further long-term monitoring as they are
potentially at an increased risk for vascular and/or cognitive events given the preclinical
changes detected and their anticipated longer overall survival. The presence of
microbleeds suggests prophylactic treatment with anti-platelet agents or anti-coagulation
as a strategy to prevent late vascular events as used in other cerebrovascular diseases may
not be advisable. Finally, this study shows that the demyelinating lesions in these patients
do have venules that are penetrating through the white matter, as shown in Figures 4.2,
4.3, and 4.4. The finding of venocentricity is similar to other disease processes with a
neuroinflammatory component, such as Multiple Sclerosis, supporting current research
investigating anti-inflammatory agents as a potential therapeutic strategy to reduce late
cerebral effects from radiotherapy.
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Chapter 5

5

Apparent Transverse Relaxation (R2*) as a method to
differentiate treatment effect and progressive disease in
pseudoprogression
5.1

Introduction

Pseudoprogression (psPD) is a diagnosis given to patients recently treated for high-grade
gliomas with chemotherapy and radiation therapy who exhibit transient post-treatment
MRI changes such as worsening gadolinium contrast enhancement within the treated
area. While psPD has been reported with radiation alone 1, this finding is most commonly
seen in the setting of combined chemotherapy and radiation for glioma. The routine
addition of Temozolomide (TMZ) to current treatment regimens for malignant glioma as
recommended by Stupp 2,3 and with evidence to support the increased use of
chemotherapy in the treatment of lower grade gliomas 4, correctly identifying psPD has
become an urgent clinical problem 5. The reason for the transient enhancement in psPD
as seen with MRI has yet to be determined; however, it has been proposed that damage to
vascular supply and neuroglial cells caused by alkylating agents such as TMZ cause an
exaggerated cellular response to radiation within the tumor. This reaction leads to
damaged astrocytes, disrupted vessel supply, inflammation, and subsequently damage to
the blood-brain barrier 6. Supporting this hypothesis is the observation that psPD is more
commonly seen in malignant gliomas with the methylated O6-methylguanine-DNAmethyltransferase enzyme (MGMT), a biomarker of increased sensitivity to treatment 7.
The increased awareness and features associated with psPD prompted revised guidelines
for the RECIST 8 and RANO 9 criteria to assist neuroradiologists and oncologists in
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interpreting post-treatment enhancing lesions. Regarding psPD, the guidelines
recommend that any T1-weighted gadolinium enhancements within the treatment area be
monitored for up to 12 weeks while maintaining adjuvant therapy. If any enhancement
appears outside the treated area, a diagnosis of progressive disease (PD) is favored.
Taking a passive approach to the monitoring of possible PD leads to anxiety for the
patient and potentially prolongs ineffective treatment with possible clinical deterioration
in patients who truly have PD. Alternatively, those with psPD who are incorrectly
identified as having PD may be switched from a potentially effective therapy to less
effective or more toxic alternatives and could skew the results of salvage clinical trials. 10.
For example, Bevacizumab is a commonly employed salvage therapy for patients for
progressive disease and has been shown to reduce enhancement through stabilization of
the tumor vasculature; however, Bevacizumab may not only reduce radiation-induced
vascular leakiness but may also lessen the efficacy of TMZ in patients who express the
MGMT promoter 11. Thus, patients with actual psPD who are most likely to respond to
TMZ could be switched to a potentially deleterious agent if incorrectly identified as PD.
Newer MRI sequences have been used in an attempt to differentiate psPD from PD with
varying degrees of success; however, there is still no clear method in which a patient with
a gadolinium-enhancing T1-weighted MRI after therapy can be differentiated between
treatment effect and PD.
Of the newer MRI sequences that have become commonplace, Diffusion Weighted
Imaging, which can measure the Apparent Diffusion Coefficient (ADC), and perfusion
MRI are currently the most applicable within a hospital setting. ADC has the distinct

97

advantage in that it can be acquired quickly and does not need a T1-altering exogenous
contrast agent. This makes it an attractive option for serial imaging; however, the
heterogeneity of the tumors has been cited as a limiting factor in differentiating between
psPD and PD using ADC 12.
Perfusion MRI, specifically Dynamic Susceptibility Contrast (DSC) MRI, has become a
useful tool to measure Cerebral Blood Volume (CBV) and Cerebral Blood Flow (CBF)
amongst other measurements. In single institution studies, increased CBV and CBF have
been found to be associated with PD, allowing successful differentiation from psPD 13,14.
DSC is the method of choice due to its speed and ease of acquisition, but may suffer from
susceptibility artifacts from air-tissue interfaces, contrast leakage, or high blood volume
areas leading to over or underestimating of rCBV 12,15. It is also difficult to standardize
across institutions 16.
Building on the previous literature, the apparent transverse relaxation rate (R2*) of
patients treated with chemoradiotherapy who exhibited transient post-treatment imaging
enhancement where there was clinical uncertainty as to whether changes were related to
psPD or PD was examined. R2* maps are calculated voxel-by-voxel using a multi-echo
gradient echo sequence and fitting the signal decay over echo time. R2* measurements
have been shown to be highly sensitive to white matter content 17, calcifications,
vasculature 18,19, and inflammation 20. An increased R2* is most often attributed to an
increased iron content from deoxygenated blood or iron-rich macrophages. A decrease in
R2* can usually be attributed to calcifications or edema.
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It was hypothesized that the differential vascular and inflammatory changes seen in PD
vs. psPD would be reflected in different patterns in the R2* maps. In particular, it was
hypothesized, based on previous perfusion literature

14,21

, that PD would be associated

with an increase in blood volume and would exhibit an increased R2*. Comparatively,
psPD would be associated with a decreased blood volume and would exhibit a decrease
in R2*. Also, it was hypothesized that susceptibility-weighted imaging (SWI) could be
helpful in distinguishing areas rich in deoxygenated hemoglobin that would correlate
with an increase in R2*.

5.2
5.2.1

Methods
Patient Selection

All patient recruitment was approved by and adhered to the University of Western
Ontario’s Human Subjects Research Ethics Board. All patients had initial surgery with
histologic confirmation of malignant glioma. They were treated according to the Stupp
protocol with combined TMZ and radiation followed by adjuvant TMZ. Standard of care
1.5T MRI imaging was used to follow patients during treatment with follow-up scans at
1-month post chemoradiation and subsequent scans after every 2-3 cycles of adjuvant
chemotherapy. Patients with possible psPD or PD were identified from the
neuroradiologist clinical report with correlation with the neuro-oncologist’s interpretation
of the imaging and clinical findings. Routine clinical imaging in this situation was an
early interval scan at 6 weeks after possible psPD was detected. Potentially eligible
patients with scans that were ambiguous for psPD vs. PD were offered participation in
this study where the additional research scan was obtained within the six-week period
before repeat clinical imaging. Patients who exhibited claustrophobia, were under the age
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of 18, or whose KPS was less than 60 were excluded from the study. The research scan
was performed between 4 to 21 days following their clinical MRI. Patients were scanned
on a Siemens 3T Prisma MRI Scanner. The patient’s clinical status and subsequent
clinical imaging after the research scan was reviewed to determine whether the patient’s
imaging changes resolved (consistent with psPD) or worsened (consistent with PD).

5.2.2

Image Acquisition

The following were acquisitions performed for this study: 1) an anatomical T1-weighted
MPRAGE sequence (FA 8°, TR/TI/TE= 2300 ms/900 ms/2.27 ms, 1 mm isotropic
resolution, scan time 4 minutes), 2) a CSF-attenuated FLAIR sequence (TR/TE
12000 ms/ 139ms, resolution 1 mm x 1 mm x 3.0 mm, scan time 5 minutes), 3) DWI (2D
EPI diffusion-weighted, b=0 s/mm2 and b=1000 s/mm2, resolution 0.6 mm x 0.6 mm
x 2.0 mm, scan time 3 minutes) and 4) a 6 echo multi-echo gradient echo sequence (MEGRE) (FA=12°, TR/TE/ESP=45 ms/6.41ms/6.12 ms, GRAPPA 2, resolution = 0.5mm x
0.5 mm x 1mm, FOV=22.4cm x 16.8cm x22.4 cm, echo fraction 5/8, scan time 12
minutes, 22 seconds).

5.2.3

Segmentation and Registration

Contrast-enhanced T1 images and FLAIR images were segmented to form the ContrastEnhancing Lesion (CEL) and Non-Enhancing Lesion (NEL), respectively. The CEL was
defined as enhancement on the clinical T1-weighted gadolinium image and the FLAIR
image while the NEL was defined as hyperintensities on the FLAIR image only. In all
cases, the enhancing lesion on the contrast T1-weighted image and FLAIR was semiautomatically segmented using ITK-SNAP 22 for manual and region growing
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segmentation and Matlab for further delineations of the CEL and NEL. The Matlab code
is included in Appendix A.
Both FLAIR and contrast-enhancing T1 were registered to the ME-GRE’s magnitude
echo average image or the computed ADC map. All images were registered using FSL’s
FLIRT toolbox using normalized mutual information 23. A contrast-enhancing T1weighted image misregistration of 1-mm was considered acceptable due to the contrastenhancing T1-weighted image being acquired on a separate day. The frontal and occipital
horns, as well as the contralateral sulci, were used as landmarks for registration.
The qualitative gadolinium-enhanced T1 and FLAIR images, and their subsequent masks,
were registered to qualitative datasets to avoid interpolation errors during registration.
The necrotic core that was surrounded by the gadolinium enhancement on T1 was not
included in the region of interest as analysis of R2* within the necrotic core was noted to
be low in both psPD and PD. Therefore, the assessment of R2* in this tumor region was
felt to be non-informative.

5.2.4

Multi-Echo Image Processing and Computation

From the ME-GRE data, an average magnitude of all echoes (MEA), SusceptibilityWeighted Images (SWI) and R2* maps were computed. SWIs were created using in-house
software using a frequency based approached initially described by Brainovich et al. 24.
The background phase was removed using an 11 mm Gaussian filter and a linear
frequency mask with a 15 Hz cutoff described by Quinn et al. 25 was used to preserve the
venous vasculature. The frequency mask was set between 0 and 1 and was multiplied
three times into the magnitude image.
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R2* maps were also computed using an in-house method fitting every voxel’s magnitude
data to a mono-exponential decay using a nonlinear least squares fit. The data were
corrected with a Voxel Spread Function (VSF) as described by Yablonskiy 26.
Mean R2* for the CEL and NEL were calculated by computing the average signal
intensity of all VSF corrected voxels within each region of interest and fitting the data
using a mono-exponential decay curve using a non-linear least squares fit as described
above. In most cases the data at each echo were normally distributed; however, in one
case the later echoes had a binomial distribution (Patient 4), this case was documented
and investigated further as described in the discussion and Figure 5.2.

5.2.5

R2* Comparisons

Comparisons of R2* between the CEL and the NEL, as well as the ratio of R2* in the CEL
to NEL, were made to determine whether differences in R2* within these regions could
provide insight into the disease pathology. The hypothesis was that the presence of
greater blood volume, a greater hypoxic region, and leakier vessels in PD would increase
the R2* in the CEL of PD patients. Conversely, lower vascular load within psPD would
lower the R2* within the CEL.

5.2.6

ADC Computations

ADC maps were processed online using the Siemens Prisma software. The same CEL
and NEL regions of interest were registered to and applied to the ADC maps. ADC
histograms were analyzed and reported as the mean and median values, unless otherwise
stated. Some patient’s ADC histograms had a binomial distribution and are documented
in Table 5.1.
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5.3
5.3.1

Results
Lesion R2*

Nine of eighteen patients imaged had useable multi-echo gradient studies. Reasons for
non-useable data included motion artifact (n=8) or magnetic susceptibility caused by the
surgical clips at the site of the craniotomy (n=1). In this specific instance, the titanium
clip interfered with the contrast-enhancing lesion leading to artificially increased R2*.
Of the nine patients who were analyzed in this study, four patients had continued
progression on subsequent imaging indicative of PD. Additionally, four patients had a
psPD at the site as indicated by improvement of subsequent imaging with one of these
four subsequently developing imaging changes that were suggestive of progressive
disease after the initial improvement. Finally, one patient had a mixed response with
imaging changes being characterized as both psPD and PD (later confirmed
histologically).
As shown in Table 5.1, patients who were subsequently diagnosed with PD had an
increased R2* within the CEL compared to the NEL with a R2* ratio of CEL/NEL > 1.3.
For patients who were diagnosed with PD, a cluster of increased R2* can be seen, as
illustrated in Figures 5.1 and 5.2.

103

Table 5.1 Reported R2* and ADC values with clinical outcome of patients
*

*

Patient

R2 CEL
-1
(s )

R2 NEL
-1
(s )

1

10.3-11.0

10.3-11.0

Mean R2
CEL/NEL
ratio
1.0

2
a
3
4

14.1-14.6
9.7-11.4
10.2-11.0

11.1-11.7
9.4-11.3
10.5-11.5

5

17.9-18.8

6
7
8

16.1-17.2
19.1-21.4
c
18.2-21.0

9

12-13.2
a

c

*

ADC CEL
Mean/Median
-6
2
(x 10 mm /s)
1358/1398

ADC NEL
Mean/Median
-6
2
(x 10 mm /s)
1315/1362

1.3
1.0
1.0

1373/1340
1456/1449
b
1172/1153

1461/1457
1475/1524
b
1274/1295

12.9-14.1

1.4

1132/1077

1009/1025

11.8-13
13.9-15.1
c
10.3-11.3

1.3
1.4
1.8

1101/1092
b
1182/1058
1328/1240b

1353/1301
b
1332/1281
b
1247/1206

c

1.0

1335/1329

1314/1329

11.4.-12.7

Outcome

psPD at site,
metastasis elsewhere
PD
psPD
psPD at site, clinical
deterioration with
reduction of steroids
PD
PD
PD
Residual tumor at
margins and necrosis
psPD followed by
progression

: ME-GRE sequence was fit over only 4 echoes due to severe motion artifact at echoes 5
and 6.
b
: ADC histogram had a binomial distribution indicative of PD and psPD.
c
: Later ME-GRE echoes had binomial distribution of data, this could be due to a mixture
of PD and psPD tissue within the lesion.

104

Figure 5.1 Patient 7 shows gadolinium enhancement on T1 (A) and FLAIR
enhancement (B) in the posterior right frontal lobe near the right frontal horn.
Corresponding R2* maps (C) shows increased R2* near the right frontal horn
indicative of tumorous tissue. Red arrow shows artefact from titanium clip, where
yellow arrow shows PD.
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Figure 5.2 Patient 8 shows both suspected necrotic lesions (psPD) (A) and tumorous
tissue (PD) (B) in separate slices. Both areas are indicated by the white arrow in the
respective panel.
Patients who were subsequently diagnosed with psPD had a similar R2* within the CEL
and NEL with a ratio of CEL/NEL =1. As well, a slightly lower R2* in the NEL of psPD
patients compared to the NEL of PD patients was observed.
A rim with an increased R2* surrounding the necrotic lesion in all patients who were
subsequently diagnosed with psPD is also observed. The increase in R2* is associated
with a decrease in FLAIR intensity and decrease signal on the SWI average as shown in
Figure 5.3.
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Figure 5.3 Patient 4 developed progression at a the frontal horn (not shown). An
example of the rim with increased R2* is shown. This is most likely a hypoxic zone as
the area appears to be rich in deoxygenated blood shown on the SWI. The SWI also
show microbleeds indicated by the white arrow
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5.3.2

ADC Values

A comparison of mean ADC values with a cutoff of 1200 x 10-6 mm2/s as suggested in
the literature 27 was performed. A mean ADC below 1200 x 10-6 mm2/s was shown to
indicative of PD and above 1200 x 10-6 mm2/s was shown to be indicative of psPD in the
referenced study. In most cases this mean cutoff agreed with the diagnosis; however, in
two of the cases, the mean ADC values did not agree with clinical outcome. Further
examination of the mean and median, as well as the clinical outcome, shows a mixed
outcome (both PD and psPD) for patient 8. Patient’s 2 mean and median ADC are both
above the cut-off that would be indicative of PD.

5.4

Discussion

A method in which quantitative R2* maps are used to differentiate PD from psPD is
presented. The findings suggest that increases of R2* in the CEL as shown by absolute
measurements and ratios of R2* in the CEL compared to the NEL may stratify patients
with PD, psPD, or mixed PD and PsPD. In particular, patients whose R2* ratio of CEL to
NEL was closer to 1 had a diagnosis of psPD upon further clinical follow-up. Those
patients with a mean R2* that was between 3-6 s-1 higher in the CEL compared to the
NEL, and a R2* ratio between the CEL and NEL >1.3, subsequently exhibited
radiographic worsening and clinical signs of PD. This is shown in Figure 5.1, where
Patient 7’s R2* is remarkably increased and subsequent imaging revealed progressive
disease.
The increase in R2* is most likely due to an increase in deoxygenated blood due to the
leakiness of the blood vessels within the tumorous tissue. It should also be noted that
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intrapatient differences of R2* between the CEL and NEL have the distinct advantage of
the possibility of multi-center implementation as the patient’s NEL could serve as their
own control metric. This would reduce variables such as scanner type dependence or
difference in magnetic field shimming that could confound the use of an absolute R2* as a
metric. Potential disadvantages are the sensitivity to motion artifact and tissue
inhomogeneities, though these can be addressed with faster R2* mapping sequences.
The R2* maps provided valuable insight into the potential disease pathology. For example,
Patient 8 showed deterioration five months after her initial psPD diagnosis and had to be
re-operated. Upon surgery, she was diagnosed with radiation-induced tissue necrosis with
infiltrating tumor at the margins of the necrotic region. The initial R2* within the CEL was
remarkably higher than the NEL, indicating probably tumor; however, the 95%
confidence of the R2* had a variation of 3 Hz, showing the possibility of a mixture of
voxels within the area of interest. As shown in Figure 5.2, most of the treated site is
surrounded by a rim of high R2*; however, there are clusters of high R2* voxels around the
treatment site hypothesized to be residual tumor. Thus the R2* imaging findings are
consistent with the later histologic picture of a mixed treatment and tumor progression
effect.
A similar clinical outcome occurred for Patient 9. While initially there was no signs of
PD, he deteriorated 3 to 4 months following his research scan visit with a follow-up
clinical scan indicative of stable disease. The R2* ratio between the CEL and NEL is
approximately 1; however, examination of the R2* map shows mild increases near the left
frontal horn which is within the initial treatment site as shown in Figure 5.4. While it was
not possible to obtain R2* measurements following his subsequent clinical visit, this case
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illustrates that serial monitoring of R2* may be useful as some patients may exhibit mixed
pictures of psPD/PD and evolution of PD after psPD.

Figure 5.4 Patient 9, initially diagnosed with psPD but presented with PD at a later
time point. The R2* map (A) corroborates psPD diagnosis; however, zoomed near
the left frontal horn, area of slight R2* increase is evident, potentially indicative of
PD.
There is a rim of increased R2* no greater than 1-1.5 mm (2-3 voxels) thick at the
interface between the necrotic core and enhancing rim of tumor in all patients. Upon
closer examination of the SWI and FLAIR, a hypointensity in this rim can be observed in
both methodologies as shown in Figure 5.3. References relating to the increased R2* in the
rim in previous literature was not found, and this unique finding requires evaluation in
larger cohorts of patients. Given the fact that changes in blood flow and volume between
PD and psPD has been noted using MR perfusion techniques, it is possible that the R2*
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rim may also be influenced by changes in blood flow. Whether the R2* rim noted could be
used as a surrogate marker for perfusion changes remains to be investigated.
In passing, it was noted that microbleeds (shown in Figure 5.3) appear around the treated
site for all patients, corroborating other findings in published literature 28–30. There was
no difference in the distribution of microbleeds within this cohort suggesting this might
not be a useful imaging biomarker for distinguishing PD from psPD. While the
quantitative measures of R2* provide us with valuable insight regarding the primary
disease, microbleed detection is best accomplished using mIP SWI maps. Whether better
assessment of microbleeds by mIP SWI maps would be a useful biomarker for psPD vs.
PD requires further investigation.
Absolute ADC values have been proposed as an effective means of distinguishing PD
versus psPD. In this series, in 7/9 patients mean ADC was able to predict PD from psPD
using a cutoff of 1200 x 10-6 mm2/s as recommended by a Lee et al. 31. In Patient 4, the
proposed ADC cutoff incorrectly identified the patient as psPD while the R2*
measurements correctly identified them as PD suggesting R2* and ADC may provide
complementary information. Given that both ADC and R2* can be acquired without
contrast, combined ADC and R2* maps may be worth exploring as an alternative imaging
biomarker for psPD compared to contrast-enhanced perfusion MRI which is preferred in
the clinic due to shorter imaging time and higher signal 12.
This study offers promise and warrants further investigation; however, some limitations
were observed throughout this study that should be refined in future research. Firstly,
patient motion artifacts were a severely limiting factor for this study. Patients were put
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into the head cradle with sufficient padding to reduce head movement; however, the submillimeter in-plane resolution acquired for the ME-GRE sequence was not robust against
motion. Additionally, the long scan time of the sequence (12 minutes) was not well
tolerated by many patients. A lower-resolution scan could be sufficient for clinical
application. A typical clinical scan’s duration ranges from 4-6 minutes, and a resolution
of 0.8mm in-plane by 1.5 mm thick axial slices would be easily achievable in this time
range. In addition to a faster sequence, there would be an increase in SNR which could
accelerate the sequence further. The use of enhanced patient immobilization devices
could also be considered to reduce patient motion but may be less practical than
optimizing the sequence parameters. Another opportunity for optimization would be
integrating the R2* imaging into the routine clinical imaging. This would reduce errors
related to registering different scans acquired on different days and in different positions.
This was seen in this study in one patient where technical difficulties in registering the
clinical and study scans precluded analysis.
Finally, this technique is also prone to susceptibility artifacts. Figure 5.1 (c) has an
excellent example of the titanium clip artifact posterior to the lesion. Also, artifacts
caused by air-tissue interfaces such as the sinuses or ear canals could hamper this
technique.

5.5

Conclusions

This research demonstrates a feasibility study in which PD can be differentiated from
treatment effect using R2*. Patients whose R2* was increased within the CEL lesion
compared to the NEL were diagnosed as true progressive disease, while patients whose
R2* had similar values between the CEL and NEL were diagnosed as having treatment
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effect. This method also shows promise to be adapted to multi-center trials as patients
could potentially serve as their own control metric using the NEL. Opportunities exist to
optimize the R2* acquisition and integrate into clinical scanning protocols to facilitate
adoption and use in larger cohorts and across institutions.
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Chapter 6

6

Conclusions and Future Work

This thesis sought to determine the feasibility of implementing a multi-echo gradient
echo sequence and its post processing techniques within the pre-clinical and clinical
environment to detect for radiation necrosis and pseudoprogression. The post-processed
images used in this thesis were SWI, R2* and QSM. The results of this thesis in both an
animal model and human patients show promise for integration within a clinical
environment. This chapter seeks to summarize the content of this thesis and discuss
relevant future work necessary for its implementation in clinical trials or within the clinic
for the long term implication of radiation to the central nervous system (Chapters 3 and
4) and patients treated with chemoradiotherapy who present with post-treatment
radiographical worsening following treatment (Chapter 5).

6.1

Context of Findings

While MRI has become an essential tool within the clinic in the diagnosis and follow-up
imaging of patients, traditional techniques are still preferred due to their proven success
and familiarity. In recent years, the increased availability of MRIs and breakthroughs in
technological advancements has rapidly made newer techniques available to attempt to
address urgent clinical problems; however, many of these techniques require longer
acquisition times or are more technically challenging, making integration within a clinical
setting difficult. As such, this thesis sought to use a widely available sequence and postprocessed images in attempts to solve clinical needs.
Chapter 3 addressed the ability of R2* to predict areas of radiation necrosis retrospectively
in a rat brain. A major challenge in the clinic is the capacity to differentiate necrosis from
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tumorous tissue using traditional T1-enhancing image and T2-weighted images 1. While
the fundamental molecular mechanisms are different in both pathologies, both exhibit
similar imaging changes. The use of ADC and perfusion techniques have been shown to
aid in differentiation of pathologies 2,3, yet once tissue necrosis is established, the tissue is
no longer salvageable and may need to be debulked should patients exhibit neurological
symptoms.
The fundamental mechanisms that lead to RN have been researched extensively over the
years as contributions from vasculature ischemia, glial cell death, and neuroinflammation
4,5

. Increases of R2* within this chapter remained non-specific as markers of histology

beyond H&E and LFB were not performed. The ability to predict changes in both the
hippocampus and internal/external capsule warrants further study as there exists a
potential of harnessing a missing link between in-vivo imaging and histology and
immunohistochemistry.
Chapter 4 addressed the usefulness of SWI, R2* and QSM as a technique that could be
used for long-term monitoring of patients who have undergone radiotherapy for benign or
low-grade neoplasms. This is the first study to show microbleeds within the high dose
region of radiotherapy with radiation alone. The long-term clinical impact of these
microbleeds remain to be established; however, as discussed in chapter 4 there is the
potential for increased risk of vascular abnormalities (e.g. stroke). In addition to this
finding, hyperintense lesions on FLAIR appear to be venocentric on SWI, R2* and QSM.
This common finding in MS is indicative of a neuroinflammatory process 6. This study
reinforces the need for long-term monitoring of these patients since their longer expected

118

OS may yield a predisposition for neurovascular disease as well as long-term necrosis,
neurological symptoms or cognitive deficits.
Finally, the findings in Chapter 5 indicate that R2* and SWI could serve as a marker to
differentiate between pseudoprogression and true progression. This technique was
effective in retrospectively determining pseudoprogression from true progression.
Additionally, this technique was demonstrated to have increased R2* within a contrast
enhancing lesion in patients with progression as well as an increase of R2* between the
contrast and non-contrast enhancing lesion. A large-scale study is needed to establish the
sensitivity and specificity of this technique with correlations to PFS and OS.

6.2
6.2.1

Future Work
Future Experiments

As was previously discussed, Chapter 3 provides a solid foundation for further research
to establish R2* as a predictor of radiation necrosis. The two most immediate refinements
that need to be addressed are correlations with histopathological findings and comparison
to a tumor model. Previous studies have shown radiation to the CNS increases the
immunoreactivity of glial fibrillary acidic protein, a marker of astrocyte activation, as
early as hours following radiation and as late as six months in mice 7,8. In addition to this
marker, increases in tumor necrosis factor alpha and intercellular adhesion molecule one
were also shown.
A comprehensive histological in a C57BL/6 mouse study showed that markers such as
MHC II expression, CD3, and CD11c are evident as early as 30 days following radiation
with up to 35 Gy 9. While one can speculate that these markers are the underlying source
of inflammation and therefore increases R2*, actual correlations would add value to this
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technique.
Additionally, comparison to the tumor model would determine whether R2* is a method
that can differentiate radiation necrosis tumor progression. The increased vasculature in
tumors may prove to be a confounding factor in the interpretation of R2*.
In Chapter 4, the main unaddressed questions are the relevance of the microbleeds within
the high dose region as well as the finding that the white matter lesions appear to be
venocentric. Venocentric lesions are common in MS and may be ground zero for the
immune response. While microbleeds appear within the high dose region in this specific
cohort of patients, a study with age-matched controls could shed further light onto the
significance of these microbleeds. Also, as was noted in the study, some of these
microbleeds appear to resolve at the one-year follow-up. The significance of this finding
demonstrates that the vascular system may still be re-adapting itself years after therapy.
The feasibility and large cohort necessary for such a long-term study limit the possibility
of pursuing this over a Ph.D. degree.
The method presented in Chapter 5 is promising; however, a larger cohort spanning many
centers is needed to address the issue of sensitivity and specificity of this technique.
Further to this specific issue, correlations with the methylation of the MGMT promoter
could add value to this technique. Methylation of the MGMT promoter has previously
been shown to correlate with pseudoprogression 10. Finding an imaging correlate of
MGMT expression would be useful as second-line salvage therapy such as Bevacizumab
is unadvised in such a patient cohort 11. Further refinements to the acquisition techniques
must be performed to make the acquisition tolerable for these patients. Patients may need
to be placed in a more confined restraint system to limit motion or techniques to increase

120

the speed of the acquisition must be taken. Increasing the voxel size may lead to a faster
acquisition; however, the appropriate voxel size should be established to optimize
imaging time with the loss of resolution (e.g. imaging small veins, microbleeds, etc.).
Other methods for a fast acquisition could include using multiband techniques to
accelerate further, using a higher GRAPPA factor. Different techniques for acquisition
such as Wave-CAIPI 12 or more common methods such as EPI could be used to acquire
images faster

6.2.2

In Closing

While there exists motivation for future work in each of the chapters, an overarching
problem with the implantation of the multi-echo gradient echo and its post-processing
techniques is the lack of standardization across multiple sites. This issue has already been
demonstrated in other techniques such as DWI and perfusion by having vendor
dependence (both scanner and software) as well as implementation dependence (use of 2
or 3 diffusion gradients) 13,14.
A consensus on the post-processing methods of multi-echo gradient echo sequences also
needs to be established. Specifically, the filtering of phase (e.g. what are considered local
and background contributors to phase) for processing of SWI, as well as the methods in
which QSM is calculated to avoid artifacts from the ill-defined problem, is needed.
The way in which R2* is calculated needs to be addressed as different methods for postprocessing exist, all adding complexity to the computation. Commercial vendors such as
Siemens provide a quick method to calculate R2*, yet as shown in Figure 6.1, there are
differences compared to a robust and computationally expensive technique such as nonlinear least squares optimization with background field correction for intra-voxel
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dephasing 15. Areas of high susceptibility and low signal appear prone to errors in
calculation while differences of R2* in the veins are also apparent.

Figure 6.1 Example of R2* calculated using the method in this thesis (NLLS),
calculation from SIEMENS, and a subtraction of the two.
In conclusion, this thesis presents new methods in which the response of the central
nervous system to radiation therapy is investigated. This non-contrast technique makes
this sequence easily implementable in routine clinical imaging and could serve as a tool
to assist neuroradiologists and neuro-oncologists to assess properly patients treated with
radiotherapy.
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Appendix A
Matlab code used to identify CEL and NEL in chapter 5:
Clear all; close all;
GADroi_nii=load_untouch_nii('GAD_on_MEA_brain_Seg.nii.gz');
FLAIRroi_nii=load_untouch_nii('FLAIR_on_MEA_brain_Seg.nii.gz');
GADroi= GADmask_nii.img;
FLAIRroi= FLAIRmask_nii.img;
GADroi (FLAIRroi ==0)=0;
FLAIRroi(GadROI==1)=0;
GADroi_nii.img=GADroi
FLAIRroi_nii.img=FLAIRroi
Save_untouch_nii(GADroi_nii,’actual_GAD_ROI_.nii')
Save_untouch_nii(FLAIRroi_nii,’actual_FLAIR_ROI_.nii')
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